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ABSTRACT
REGULATION OF MTORC1 BY HOMOCYSTEINE AND ITS EFFECTS ON
AUTOPHAGY IN HUMAN AND MOUSE NEURONAL TISSUES
By
Khoosheh Khayati
The molecular mechanisms leading to and responsible for age-related, sporadic
Alzheimer’s disease (AD) remain largely unknown. It is well documented that aging
patients with elevated levels of the amino acid metabolite homocysteine (Hcy) are
at high risk of developing AD. The impact of Hcy on molecular clearance pathways
in mammalian cells, including in-vitro cultured induced pluripotent stem cellderived forebrain neurons and in-vivo neurons in mouse brains is investigated in
this research project. Exposure to high Hcy levels results in up-regulation of the
mechanistic target of rapamycin complex 1 (mTORC1) activity, one of the major
kinases in cells that is tightly linked to anabolic and catabolic pathways. Moreover,
Hcy-mediated mTORC1 activity is only specific to Hcy and not to Hcy metabolites
such as Hcy-thiolactone and cysteine. Homocysteine is sensed by a constitutive
protein complex composed of leucyl-tRNA-synthetase (LeuRS) and folliculin
(Flcn), which regulates mTOR tethering to lysosomal membranes. In hyperhomocysteinemic human cells and cystathionine β-synthase-deficient mouse
brains, an acute and chronic inhibition of autophagy, the molecular clearance
pathway is detected. In Hcy-treated cells, mTORC1 mediates phosphorylation of
ULK1 which consequently reduces LC3 lipidation. mTORC1 also dampens TFEBdriven transcription of autophagy-related genes resulting in a buildup of abnormal
proteins, including β-amyloid and phospho-Tau. Formation of these protein
aggregates leads to AD-like neurodegeneration. This pathology can be prevented

by inhibition of mTORC1 or by induction of autophagy, through TAT-Beclin1
treatments. Here it is discussed that an increase of intracellular Hcy levels
predisposes neurons to develop abnormal protein aggregates, which are
hallmarks of AD and its associated onset and pathophysiology with age.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

1.1 mTOR is a Major Integrator of Signaling Pathways in the Cell
As a serine-threonine kinase and a member of phosphoinositide-3-kinase (PI3K)
related kinase family, the mechanistic target of rapamycin (mTOR) is a central
hub for various anabolic and catabolic pathways in the cell (Laplante and
Sabatini 2012; Wullschleger, Loewith, and Hall 2006; Loewith and Hall 2011).
Both synthetic pathways such as protein and lipid production as well as breakdown processes such as autophagy are influenced by mTOR activity (Laplante
and Sabatini 2012) (Figure 1.1). Being observed along with other components in
two different complexes, mTOR is the catalytic subunit in both mTORC1 and C2.
Nutrient and growth factor signaling are mainly attributed to mTORC1 while
cytoskeleton regulation, cell growth, and death are known to be controlled by
mTORC2 (Laplante and Sabatini 2012; Guertin et al. 2006; Sarbassov et al.
2004).

1.2 mTORC1 and Amino Acid Signaling
Mechanistic target of rapamycin complex 1 has been identified in two different
states, either active or inactive. mTORC1 exists in diffused form throughout the
cytoplasm in its inactive phase while localizes on the lysosomal membrane as an

1

Figure 1.1 Cellular signaling regulates mTORC1 activity through the TSC
complex. The TSC complex represents a hub for incoming cellular signals
ranging from hypoxia, DNA damage, and energy levels to growth factors, Wnt,
and TNF signals. Signaling mediators and/or kinases modulate the GAP activity
of the TSC complex to inhibit or activate Rheb. An inactive TSC complex results
in activation of mTORC1 thereby promoting protein and lipid synthesis, energy
metabolism, and inhibition of lysosomal biogenesis and autophagy.
Source: Khayati, K., Nnah, I. C., and Dobrowolski, R., 2015. “Cellular Metabolism and
Lysosomal mTOR Signaling.” Cell Death in Therapy, 11-22.

active kinase along with other lysosomal membrane proteins which form the
lysosome nutrient sensing (LYNUS) machinery (Settembre et al. 2013). LYNUS
machinery is comprised of Rags (small GTPases in form of heterodimer) which
act as docking sites for mTORC1 to tether on the lysosomal surface (Sancak et
al. 2010), v-ATPase, a proton pump that acidifies the lysosomal lumen and plays
prominent role in sensing amino acids availability inside the lysosome (Ohkuma
1982), Ragulator, a guanine nucleotide exchange factor (GEF) for Rag A and B
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GTPases (Sancak et al. 2010; Huang and Fingar 2014) and finally endosomal
ATP-sensitive sodium ion-permeable channel which responds to ATP levels and
regulates lysosomal membrane potential and pH stability (Cang et al. 2013). The
reason for mTORC1 translocation on the lysosomal membrane as part of the
LYNUS machinery is for being in close proximity with its activator, Ras homolog
enriched in brain (Rheb) which is known as a small GTPase residing on the
lysosomal membrane (Inoki et al. 2003; Tee et al. 2003). This mTORC1
recruitment to lysosomal membrane largely depends on the availability of amino
acids which are sensed by the LYNUS machinery, a process that is critical for
mTORC1 to be able to regulate its downstream pathways (Sancak et al. 2010).
This way, amino acids regulate mTORC1 activity by regulating its proximity to
Rheb. So, amino acids are not only considered as building blocks of proteins but
also play important roles in the maintenance of cellular homeostasis through
activation of mTORC1 (Laplante and Sabatini 2012); among them, leucine (Leu)
is known as the most potent one in regards to mTORC1 activation (Bar-peled
and Sabatini 2014).

1.3 Inside-Out Mechanism of Amino Acid Signaling through v-ATPase
Vacuolar 𝐻 + - adenosine triphosphatase (v-ATPase) is known as a proton pump
which acidifies lysosomal lumen by hydrolyzing ATP and production of a proton
gradient. This proton gradient is usually coupled with symport/antiport
mechanism of amino acid transporters (Russnak, Konczal, and Mcintire 2001). VATPase consists of V0 and V1 domains. V1, the cytoplasmic domain is
3

responsible for ATP hydrolysis that induces a conformational change in the
integral membrane domain, V0. This integrated action of both domains promotes
influx of protons across the endolysosomal membrane (Forgac 2007). In addition
to its prominent role in vacuolar pH maintenance, v-ATPase is the main factor in
sensing amino acid availability in the lysosome in order to regulate mTORC1
activity (Zoncu 2011). By inhibiting the expression of genes encoding for vATPase components and assessing mTORC1 activity, Zoncu et al. showed a
strict dependence of mTORC1 on v-ATPase function. Furthermore, cells treated
with Concanamycin A, a v-ATPase inhibitor, failed to recruit mTORC1 to their
lysosomal membranes even in presence of amino acids. Therefore, it was
proposed that upon amino acid availability, v-ATPase relays the signal to
Ragulator, the Rag A/B activator, through which active Rags are bound on
lysosomal surface which further facilitate tethering of mTORC1 to the complex
(Zoncu 2011). Later, Stransky and Forgac showed that amino acid availability
influences v-ATPase assembly and function as well, which in turn is crucial for
culmination in mTORC1 activity (Stransky et al. 2015).

1.4 Amino Acids can be Sensed and Edited through Interaction with
Aminoacyl-tRNA Synthetases in the Cytoplasm
Aminoacyl-tRNA synthetases (AARS) are enzymes generally known to facilitate
binding of amino acids to their cognate tRNA (Serre et al. 2001). The so-called
tRNA charging with amino acids is a two-step process consisting of binding of
amino acid to AARS and being transferred to their cognate tRNAs; the later step
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is called tRNA aminoacylation (Giegé 2008). During tRNA charging, amino acidbound AARS conjugates with AMP (an intermediate with high energy level) which
later favors a high-energy ester bond formation between an amino acid and 3’terminal of the tRNA (Jakubowski 2012). Among AARSs, leucyl-tRNA synthetase
(LeuRS) is the enzyme that promotes the transfer of Leu to its counterpart tRNA
and is proposed to act as an important player in protein translation as well as
being an mTORC1 activator by sensing available Leu in the cytoplasm (Han et
al. 2012).
In addition to their regular function in amino acid selectivity for tRNAs,
AARSs are found to be able to edit non-proteinogenic amino acids such as
homocysteine (Hcy). Inaccurate amino acids need to be edited in order to inhibit
their incorporation into our proteins. Among AARSs, isoleucyl-tRNA synthetase
(IleRS), valyl-tRNA synthetase (ValRS), lysyl-tRNA synthetase (LysRS) and
LeuRS are known to edit Hcy (Jakubowski 2011). In general, amino acid editing
by AARSs takes place in two ways: pre-transfer editing (edition of amino acids
while they are bound to AARSs prior to tRNA binding) and post-transfer editing
(amino acid editing after transfer to tRNAs) (Cvetesic, Perona, and Gruic-sovulj
2012).
Weak interaction between the side chain of the amino acid, which is
recognized by an AARS, and the active site of the enzyme triggers editing
process of non-proteinogenic amino acids. In the case of methionyl-tRNA
synthetase (MetRS), amino acid charging and editing happen at the same active
site of the enzyme which recognizes both methionine (Met) and Hcy. Methionine
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binding to MetRS induces rearrangement in the active site of the enzyme through
which aminoacylation is triggered, while Hcy fails to induce such rearrangements
(Serre et al. 2001).
In general, in process of editing, an amino acid conjugated with AMP or tRNA, undergoes hydrolysis reaction which gives rise to the production of a free
amino acid. But if amino acid has a nucleophile group such as γSH in Hcy, it will
be converted to a cyclized form of amino acid (thiolactone in the case of Hcy)
(Lincecum et al. 2003). Homocysteine-thiolactone formation through MetRS is
highly conserved in bacteria, yeasts, plants and humans and prone to
aggregation and excretion in urine because of the low dissociation constant (pK =
6.65) of its amino group (Jakubowski 2011). Methionyl-tRNA synthetase has a
thiol-binding sub-site through which editing of Hcy occurs. There is competition
between the side chain of amino acid and tRNA in binding to the carboxyl group
of amino acid. Methyl group of Met binds firmly to specificity sub-site of MetRS
through hydrophobic and hydrogen bonds, renders its carboxyl group free to bind
to tRNA; while thiol group of Hcy is deficient in binding to specificity sub-site of
MetRS, though wins the competition over tRNA in binding to carboxyl group of
Hcy and produces cyclized Hcy-thiolactone (Serre et al. 2001). It is noteworthy
that Hcy-thiolactone is very reactive and prone to damage protein structures by
binding to amine groups of lysines incorporated into proteins leading to the
formation of N-Hcy-proteins (Jakubowski, Boers, and Strauss 2008). Two
enzymes which specifically hydrolyze Hcy-thiolactone back to Hcy, are bleomycin
hydrolase (Blmh) and paraoxonase1 (Pon1). Bleomycin hydrolase-deficient mice
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exert 1.8 fold more Hcy-thiolactone in their urine as compared to normal mice
(Borowczyk, Tison, and Jakubowski 2012).

1.5 Leucyl-tRNA Synthetase or Folliculin; Which One Acts as a GTPase
Activating Protein for Rag C/D?

Upon introduction of LeuRS as a sensor for Leu availability in the cytoplasm, a
further investigation was carried out to unveil the mechanism through which
LeuRS relays the signal to mTORC1. Immunoprecipitation analyses between
LeuRS and Rags along with in-vitro GTPase assays implicated LeuRS as a
GTPase-activating protein (GAP) for Rag D (Han et al. 2012). Follow-up
analyses, however, failed to confirm LeuRS as the active GAP of RagD but
identified Folliculin (Flcn) to be the protein to carrying out these function. Being
first identified as a tumor suppressor whose loss of function leads to Birt-HoggDube syndrome with characteristics including formation of benign tumors in hair
follicles, lung and renal system (Nickerson et al. 2002), Flcn has been related to
various pathways in the cell such as mTOR signaling, transforming growth factor
β (TGF-β) signaling, AMP-activated protein kinase (AMPK) signaling, JAK-STAT
signaling, cell adhesion, membrane traffic and cilia function (Petit, RoczniakFerguson, and Ferguson 2013). Notably, Petit et al could shed light on a new
function of Flcn in translocation of transcription factor EB (TFEB) between
nucleus and cytoplasm; in that nuclear localization of TFEB was observed in Flcn
knockdown cells. They also found Flcn function necessary for re-activation and
lysosomal localization of mTORC1 after deprivation and replenishment of amino
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acids consequently (Petit et al. 2013). In the search for implicating the
significance of Rag C and D in amino acid signaling machinery, Tsun et al could
substantiate GAP activity of Flcn towards Rag C and D (Tsun et al. 2013). Amino
acid deprivation induces Flcn interaction with the lysosomal membrane,
specifically to Rag C/D which is diminished by replenishment of amino acids.
Accordingly, Flcn needs to detach from the lysosomal membrane to be replaced
by mTORC1 in presence of amino acids (Tsun et al. 2013). Similar to Flcn,
Folliculin interacting protein (FNIP) indirectly regulates mTORC1 activity and
TFEB localization as suppression of FNIP induces nuclear localization of TFEB
(Petit et al. 2013). Taking into account that FNIP is necessary for interaction of
Flcn and Rags and Flcn is also necessary for FNIP-Rags interaction, Flcn and
FNIP are considered as components of a complex in which both proteins should
be active in order for Flcn to show GAP activity towards Rag D (Petit, RoczniakFerguson, and Ferguson 2013; Tsun et al. 2013); since neither Flcn nor FNIP
shows the activity, separately (Tsun et al. 2013).
The notion that suppressing both LeuRS and Flcn expression inhibits
translocation of mTORC1 to the lysosomal membrane in response to amino acid
availability (Han et al. 2012; Tsun et al. 2013), inspired us to assess the
possibility of LeuRS interaction with Flcn in a complex.
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1.6 Homocysteine; a Non-Proteinogenic Amino Acid
In addition to essential and non-essential amino acids that are used for protein
synthesis, there are amino acid metabolites some of which are detrimental to the
cells (Dasuri et al. 2011). These side products, the so-called non-proteinogenic
amino acids, need to get removed from the protein translation pathway to inhibit
error insertion in proteins and formation of misfolded proteins that ultimately lead
to cell death (Lee et al. 2006). Homocysteine, a known sulfur-containing nonproteinogenic amino acid results from demethylation of Met (Prudova et al. 2006)
and has been identified as a risk factor for cardiovascular disease (Garcia and
Zanibbi 2004; Zhuo, Wang, and Pratico 2011). When plasma Hcy concentration
exceeds 14 μM, we encounter hyperhomocysteinemia (HHcy), a pathological
state which is linked to cardiovascular disease, neuronal cell death along with the
loss of short and long-term memory (Ataie, Sabetkasaei, and Haghparast 2010;
Zhuo et al. 2011; Kamat et al. 2013). Hyperhomocysteinemia has also been
associated with Alzheimer’s disease (AD), schizophrenia and depression
(Folstein et al. 2007).
In process of losing a methyl group, Met converts to S-adenosine
methionine (SAM) and eventually Hcy. Homocysteine needs to get re-methylated
in order to convert to Met. 5-methyltetrahydrofolate, known as folic acid and SAM
are main methyl donors to Hcy. Notably, methylenetetrahydrofolate reductase
(MTHFR) and methionine synthase (MS) are the enzymes driving the remethylation pathway, though are important in the elimination of Hcy from the
body (Chiang et al. 1996). The alternative enzyme proposed to have a positive
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effect on the removal of Hcy is cystathionine β- synthase (CBS); the enzyme
which demands vitamin B6 as an efficient cofactor to function optimally. The
product of CBS activity is cystathionine which will ultimately be converted to
cysteine and α-keto butyrate through a second enzymatic step (Jakubowski
2012).
Given that Hcy is a modified form of Met, it is possible that Hcy can be
sensed by mTORC1 through AARS. The impact this Hcy may have on mTORC1
activity was evaluated in this dissertation.

1.7 mTORC1 Negatively Regulates Autophagy
The transcription factor EB is a member of the basic helix-loop-helix leucine
zipper family of transcription factors and shown to be a substrate of mTORC1
(Sardiello et al. 2009). Upon mTOR-mediated phosphorylation of TFEB at serine
211, TFEB interacts with the 14-3-3 protein which blocks TFEB’s nuclear
localization signal. This way, phosphorylated TFEB remains in the cytoplasm
(Martina et al. 2012; Roczniak-ferguson et al. 2012). Unphosphorylated TFEB
translocates into the nucleus where it binds to a 10-base pair DNA motif
(GTCACGTGAC), the so-called Coordinated Lysosomal Expression and
Regulation (CLEAR). The CLEAR element is part of the promoter of genes
encoding lysosomal and autophagosomal proteins (Sardiello et al. 2009) (Figure
1.2). Thereby, TFEB induces lysosomal biogenesis and autophagy, a cellular
self-eating process for degradation of protein aggregates and old organelles in
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the cytoplasm (Glick, Barth, and Macleod 2010). Two of the crucial autophagyrelated TFEB target genes are ubiquitin-binding protein P62, (an adaptor protein
that detects ubiquitinated protein aggregates and recruits them to the
degradation initiation site, autophagosomes) (Lamark et al. 2009), and
microtubule-associated protein 1 Light Chain 3 (LC3), which is necessary to
detect targets selected for macro-autophagy degradation. LC3 is a member of
Atg proteins which is either cytosolic (LC3-I) or membrane-bound (LC3-II). The
transition between the two forms of protein occurs by cleavage of LC3 on its Cterminal domain through a cysteine protease (Atg4) that is believed to expose it
to further post-translational modification known as covalently phosphatidyl
ethanolamine conjugation (Marino et al. 2002). The later modification renders
LC3-II capable of binding to inner and outer part of autophagosomal membranes.
Since

LC3

detects

ubiquitinated

proteins

and

sequesters

them

in

autophagosomes through the help of adapter proteins, ubiquitination could be
considered as a signal for both proteasomal degradation and selective
autophagy. The distinguishing factor deciding whether proteins should undergo
proteasomal degradation or selective autophagy is binding of proteins to UBD
(ubiquitin-binding domain)-containing autophagy receptors (such as P62) that
simultaneously bind to Atg8 (LC3) proteins (Slobodkin and Elazar 2013).
However, P62 is not dependent on LC3 to be recruited to autophagosomes; the
PB1 (Phox1 & Bem1p) domain of p62 has been shown to be sufficient for its
recruitment to autophagosomes, and starvation indeed boosts this process
(Itakura and Mizushima 2011).
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Figure 1.2 TFEB translocation in and out of the nucleus. Phosphorylation of
TFEB by mTORC1 determines its localization; as phosphorylated TFEB is kept in
the cytoplasm while unphosphorylated form enters the nucleus to render its role
on transcription of CLEAR-gene network.

The alternative factor which is influenced by mTORC1 activity and
consequently affects autophagy initiation is unc-51 like autophagy activating
kinase-1 (ULK1) which contains several phosphorylation sites that regulate its
activity. Having a dual function in autophagy regulation, ULK1 is phosphorylated
on various sites which determine its role in autophagy. Phosphorylation of ULK1
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on serine 317 and serine 777 by AMP-activated protein kinase (AMPK) are
crucial for induction of autophagy, while mTORC1 kinase activity on serine 757 of
ULK1 hampers AMPK interaction to ULK1 and inhibits autophagy pathway (Kim
et al. 2011).

1.8 Low Rates of Autophagy in Alzheimer’s Disease Patients’ Brains
As a protective mechanism, autophagy is initiated in response to abnormal
conditions in the cells such as hypoxia, low energy level due to lack of amino
acids and growth factors, aggregation of proteins, DNA damage (Mathew,
Karantza-wadsworth, and White 2007) and metabolic stress (Levine and
Kroemer 2008). Observation of enlarged autophagic vacuoles in patient cells of
AD (Nixon and Yang 2011), Parkinson’s and Huntington’s diseases raised the
speculation as whether autophagy is the cause for initiation of these diseases or
can be used as a strategy to ameliorate the pathology of these conditions
(Rubinsztein et al. 2007; Williams et al. 2006; Martinez-vicente and Cuervo 2007;
Levine and Kroemer 2008). As autophagy is shown to remove paired helical
filaments of tau protein aggregates (Williams et al. 2006), it is more compelling
that autophagy has a positive impact on hampering of neurodegeneration and
clearance of abnormal protein accumulations. On the other hand, AD is
discussed by some researchers as a Lysosomal Storage Disease (LSD) due to
lysosomal enzymes malfunction in degradation of cargos transported there
(Nixon, Yang, and Lee 2008). Since aggregated proteins are large and can be
cleared only by specific pathways in the cytoplasm such as macroautophagy, it is
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significant for the pathway to run efficiently (Martinez-vicente and Cuervo 2007).
To date, there is no evidence why autophagy is impaired in AD neurons. Here we
introduce Hcy as one of the risk factors of AD and a possible inhibitory agent of
autophagy.

1.9 Significance and Introduction to Dissertation Project
Dysregulation of mTORC1 activity has been correlated with the pathology of
several human diseases such as cancer (Bar-peled et al, 2014), metabolic
diseases, neurodegeneration, and aging process (Laplante and Sabatini 2012).
Especially in the case of neurodegeneration, since intact autophagy and
proteasomal protein degradation are known to have an important impact on
inhibition of the disease onset (Rubinsztein 2006), mTORC1 signaling as a
regulator of autophagy pathway has received attention and been the center of
study in the field. By assessing mTORC1 activity in postmortem brains of human
AD patients, we found up-regulation of mTORC1 kinase activity in AD samples
as compared to controls (Figure 3.1 A). In parallel, high plasma levels of Hcy has
been recorded for those AD patients as a highly plausible risk factor (Zhuo,
Wang, and Pratico 2011; Li, Chu, and Barrero 2014; Kamat et al. 2015). Studies
on Cbs deficient mice mated with double transgenic APP/PS1 mouse model of
amyloidosis show that Hcy changes the ratios of the produced βA42 and βA40
peptides to drive the amyloidogenic pathway (Pacheco-quinto et al. 2006).
Moreover, a group of B vitamins has implicated inhibitory effects on brain
shrinkage and cerebral atrophy in patients with HHcy, diagnosed with AD
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(Douaud et al. 2013). Additionally, substantiated data show that vitamin B12
deficiencies lead to cognitive impairment by induction of HHcy which is also
linked to methylation deficiencies of myelin basic protein leading to neuronal
defects (Sponne et al. 2000).
Taken together, all these data support the notion that Hcy might elicit AD
phenotype through different pathways, from activation of NMDA transporters
(Lipton et al. 1997), to increase in activity of β-secretase (BACE) (Fuso et al.
2005) and γ-secretase (Li et al. 2014). Yet, there is no link provided between
Hcy-mediated mTORC1 activity and generation of AD phenotype. Here, we
assess whether and how Hcy can be sensed by mTORC1 and explore the
correlation between high plasma Hcy levels, mTORC1 hyperactivity, and
autophagy inhibition in human and mouse neurons.

1.10 The Hypothesis of the Dissertation
Given that Hcy and mTORC1 activity, both are elevated in AD patients, it is
worthwhile to evaluate Hcy contributions to mTORC1 activity and consequently
on autophagy. In this dissertation we examined this hypothesis: Leucyl-tRNA
synthetase (LeuRS) (an enzyme is known to load tRNA with leucine)
regulates the activity of Folliculin (Flcn) (an mTORC1 activator) in a
homocysteine/leucine-dependent manner; mTORC1 hyperactivity inhibits
autophagy by phosphorylation of TFEB (a transcription factor) or ULK-1 (an
autophagy inducer) and leads to neurodegeneration. To test this hypothesis
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we utilized mainly HEK293T cells and iPSC-derived human neurons for in-vitro
studies, as well as Cbs knockout mice for in-vivo analyses, and accomplished the
following:
1. Elucidated Hcy effect on mTORC1 activity in cells treated with Hcy and
Cbs knockout mouse brain samples.
2. Elucidated how LeuRS and Flcn cooperatively sense levels of cellular
amino acids and their metabolites to activate mTORC1 in the Cbs deficient brain
and cultured cells.
3. Determined rate of autophagy induction in HEK293T cells and human
neurons treated with Hcy.
4. Determined TFEB activity in Hcy-treated cells and Cbs knockout mice
brain samples.
5. Evaluated the role of Hcy in neurodegeneration and cell viability.
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CHAPTER 2
MATERIAL AND METHODS

2.1 Materials
2.1.1 Cell Lines
2.1.1.1 HEK293T Cells.

HEK293T cells are human embryonic kidney cells

cultured and maintained in Dulbecco’s modified Eagle’s medium (DMEM) with
10% Fetal Bovine serum (FBS), L-glutamine (Glu) and penicillin/streptomycin
(Pen/Strep).

2.1.1.2 Human iPS Cells. Human neural stem cells (also called neuroprogenitor
cells) were generated in our lab using previously established human iPSC lines
and following dual-SMAD inhibition protocols using SB431542 (10µM, Stemgent)
and LDN193189 (250nM, Stemgent) drugs for at least three weeks and until the
formation of neural rosettes was obvious. Neural rosettes were micro-dissected
under a microscope in sterile environment (cell culture hood), trypsinized to
dissociate into single cells, and maintained in neuroprogenitor basal media
(#05834 Stem Cell Technologies) including supplement A (#05836) and
supplement B (#05837) and differentiated to human forebrain neurons in
neurobasal media supplemented with B27 without vitamin A (#12587-010),
Glutamax and Pen/Strep, for at least three weeks. Successful differentiation has
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been confirmed in immunofluorescence analyses showing loss of progenitor
marker expression (Nestin) and gain of neuronal marker expression (Tuj1,
MAP2, Synapsin1).

2.1.1.3 CAD cells. CatecholAminergic Differentiated (CAD) cells are mouse
neuroblastoma cells. CAD cells stably expressing TFEB under a doxycycline
(DOX) sensitive promoter were established in our lab and cultured in normal
DMEM 10% FBS similar to HEK293T cells.

2.1.1.4 MEF cells. Mouse Embryonic Fibroblasts (MEFs) were cultured and
maintained in DMEM supplemented with 10% FBS.

2.1.2 Animals
Transgenic Tg-I278T 𝐶𝑏𝑠 −/− mice on C57BL/6J genetic background and their
𝐶𝑏𝑠 +/− littermates were bred and housed at the New Jersey Medical School
Animal Facility. In these animals, the human CBS-I278T variant is under control
of the zinc-inducible metallothionein promoter, which allows rescue of the
neonatal lethality phenotype of 𝐶𝑏𝑠 −/− by supplementing the drinking water of
pregnant dams with 25 mM zinc chloride. Zinc water is replaced by plain water
after weaning. The mice were fed a normal rodent chow (LabDiet5010, Purina
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Mills International, St. Louis, MO). 12-month-old animals were used for
immunohistochemistry studies.

2.1.3 DNA constructs
Plasmids were kindly provided by following laboratories: pRK5-HA GST RagC
plasmids (Addgene #19304, 19305, 19306, Cambridge, MA, USA) and FlagLeucyl tRNA synthetase pRK5 (Addgene #46341) were gifts from Dr. David
Sabatini

(Whitehead

Institute,

Massachusetts

Institute

of

Technology,

Cambridge, MA, USA), ptfLC3 (Addgene #21074) was a gift from Dr. Tamotsu
Yoshimori

(Osaka

University,

Osaka,

Japan),

and

ptdTomato-N1-FLCN

(Addgene #49174) was a gift from Dr. Shawn Ferguson (Yale School of
Medicine, NewHaven, CT, USA). The CLEAR-Luciferase construct was a
generous gift from Dr. Andrea Ballabio (Telethon Institute of Genetics and
Medicine (TIGEM), Pozzuoli, Italy).

2.1.4 Antibodies
The following were used as primary antibodies for immunostaining and
immunoblotting:

AKT (#4691P, Cell Signaling),

Amyloid (#D54D2, Cell

Signaling), β-Actin (#JLA20, DSHB), Flag (#F3165, Sigma), Flcn (#D14G9, Cell
Signaling), HA (#024M4773, Sigma), mouse LAMP2 (#ABL-93, DSHB), human
LAMP2 (#H4B4), LC3 a/b (#4108, Cell Signaling), LeuRS (#sc-130801, Santa
Cruz), MAP2 (#ab5392, Abcam), mTOR (#7C10, Cell Signaling), P-4E-BP1
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(#236B4, Cell Signaling), p62/SQSTM1 (GP62-C, Progen), P-Akt (Ser473,
#4060P, Thr308, #2965P, Cell Signaling), P-p70S6K (Thr389, #9205, Cell
Signaling),

P70S6K

(#2708,

Cell

Signaling),

PHF

pTau

(#MN1020,

ThermoFisher), PULK1 (Ser 757 #D706U, Cell Signaling), RagC (Rag antibody
sampler kit, #9778, Cell Signaling), Rheb (#E1G1R, Cell Signaling), Sestrin2
(#10795-1-AP, ProteinTech), TFEB (#MBS120432, Abcam for immunostaining;
#ab2636, Abcam, for immunoblotting, and #A303-673A, Bethyl Biosci. for
immunohistochemistry), Tuberin/TSC2 (#D93F12, Cell Signaling), Tubulin
(#CP06, Calbiochem). Secondary antibodies were coupled to Infrared Dyes
(LICOR, IRDye 680 and IRDye 800) or to HRP (Jackson IR) for immunoblotting,
or to fluorochromes (Jackson IR) for immunostaining.

2.1.5 Chemicals
RPMI media without leucine/glutamine was supplied by US Biological. Amino
acid starvation experiments were performed in the same media supplemented
with L-glutamine (#R899912) and 10% dialyzed FBS (Reddy et al. 2016). RPMI
complete media was prepared by addition of L-leucine (#L800) to the starvation
media. DMEM provided by Sigma were supplied with glutamine, Fetal Bovine
Serum (gibco), penicillin and streptomycin (gibco). Rapamycin was provided by
Sigma (#R0395), and TAT-Beclin1 by EMD Millipore/Sigma (#5060480001).
Amino acids (Sigma-Aldrich) were reconstituted in water. L-Hcy (#69453) and LLeucinol (#CDS005275) were supplied from Sigma.
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2.1.6 Microscope
Spinning disc confocal microscope (Zeiss, Oberkochen, Germany) with lasers
emitting 488, 536/561, 639 and 405 nm laser lines and 63X oil immersion
objective was used for immunofluorescent imaging of this study.

2.2 Methods
2.2.1 Immunofluorescence
Cells were plated on coverslips coated with fibronectin, for one hour and fixed
with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were
incubated with primary and fluorophore-tagged secondary antibodies and
subjected to imaging in confocal microscopy.

2.2.2 Immunohistochemistry
Mice were perfused transcardially under deep pentobarbital anesthesia. Brains
were collected, post-fixed in 4% PFA, and cryoprotected in 30% sucrose in PBS
solution prior to sectioning. Thirty µm thick hippocampal brain sections from PFA
perfused mice were rehydrated with PBS and permeabilized with 1% Triton X100 in PBS for 30 mins. The sections were washed 3 times for 10 minutes with
PBS-Triton buffer (0.05% Triton X-100 in PBS), incubated in blocking buffer (50%
NGS, 50% PBS-Triton buffer) for 2 hours, and in indicated primary antibody
solution (50% blocking buffer, 50% PBS-Triton X-100) overnight at 4°C in
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humidity chambers. The sections were washed with PBS-Triton buffer and
incubated with fluorescently-labeled secondary antibodies for 2 h at room
temperature and mounted. Sections were imaged with a Zeiss spinning disc
confocal microscope, taking a Z-stack of 29 sections with an interval of 0.48μm
and range of 13.45μm.

2.2.3 SDS-PAGE and Immunoblot
Cells were resuspended in lysis buffer (10% glycerol, 1% NP40, 20mM Tris
(pH7.4), 2.5mM EDTA (pH8), 2.5mM EGTA (pH8) containing Roche Protease
inhibitor

cocktail

(#04693116001)

diluted

according

to

manufacturer’s

instructions) and cell lysates were centrifuged at 14000 rpm for 15 minutes at
4°C. The cleared supernatants were collected and prepared for SDS-PAGE on
10 or 12% mini gels; protein concentrations were determined using BCA reagent.
Resolved proteins were transferred onto PVDF (Immobilon) membranes followed
by a 45-minute room temperature incubation in western blocking solution (5%
milk, 0.1% Triton X-100 in TBS). The membrane was incubated with primary
antibodies overnight and with secondary antibodies for 45 minutes. After washes
in TBS-T, the membranes were analyzed using either an LI-COR Odyssey
system or film exposures of luminescence generated by ECL (Pierce) for HRP.
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2.2.4 Co-Immunoprecipitation
HEK293T cells were transfected with HA-RagC (wild type, constitutively active
and dominant negative), LeuRS-Flag and Flcn-dTomato plasmids, separately
followed by overnight culturing to reach appropriate confluency. IP-buffer (50mM
Tris, 150 mM NaCl, 10mM EDTA, 1% NaF, 1% Na3VO4, 1% NP40, 0.5 mM
DTT, 1x Complete Protease Inhibitor Cocktail (Roche)) was used for lysing the
cells. Lysates were cleared by centrifugation and incubated overnight with antiHA/Flag antibodies at 4°C followed by overnight incubation with MagnaBind goat
anti-rabbit/mouse beads (ThermoScientific) on a rotating mixer. After incubation,
the beads were washed 3X with IP-buffer and then resuspended in Laemmli
buffer and boiled for 10 mins. The IP protein samples and protein input were
analyzed by SDS-PAGE and immunoblotting to examine endogenous LeuRS,
Flcn, and RagC in all cell lines under different feeding conditions.

2.2.5 EGFP-mRFP-LC3 Assays
To assess the maturation and amount of active autophagosomes, ptfLC3
constructs were transiently transfected into iPSC-derived human forebrain
neurons. After 48 hours, some cultured cells were incubated with 100 uM
Chloroquine for up to 1 hour to inhibit autophagy flux. Cells were fixed with 4%
PFA, mounted and imaged. Images from approximately 100 cells per treatment
were collected and quantified for the number of red puncta (mRFPLC3 signal)
per cell; the GFP signal was recorded blindly, using same exposure times and
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laser strength settings as for the RFP channel. A yellow signal indicates not
acidified, immature autophagosomes.

2.2.6 Luciferase assays
4xCLEAR Luciferase construct containing four times repeated CLEAR element
upstream of Firefly-luciferase gene has been used to assess the activity of TFEB
and CLEAR gene network. In this assay, TFEB binding to CLEAR promoter
drives the transcription of TFEB-regulated genes and luciferase. Luciferase
transcription is assessed in Dual-luciferase Reporter assays (Promega) for which
cells were seeded in a 24 well plate and co-transfected with 4xCLEAR Luciferase
and SV40 Renilla luciferase plasmids. SV40 Renilla luciferase was used as a
transfection control. Twenty-four hours after transfection, cells were harvested in
passive lysis buffer (Promega) and, after short centrifugation separating cellular
membranes and DNA, 10 µl of pre-cleared lysate were used to assay luciferase
activity using the Promega Dual-Luciferase Reporter kit and GloMax Multi+ plate
reader.

2.2.7 Aβ Assays
Fully differentiated human forebrain neurons or mouse brain tissues were
resuspended in the standard diluent buffer supplied by the manufacturer (Wako).
To quantify Aβ levels human/mouse Aβ 1-40 and 1-42 ELISA kits (Wako) were
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used according to the manufacturer’s instructions. All assays were repeated 3
times and averaged for each triplicate.

2.2.8 Quantification and Statistics
All immunoblot signals were quantified using ImageJ software. To assess the
number or co-localization of autophagosomes, lysosomes, and protein
aggregates their specific, punctuate staining was quantified using ImageJ
software and plugins for measuring intensity maxima from images based on
individual parameters, or individually counted. Statistical evaluation of the
collected data was performed using the student t-test and analysis of variance
(ANOVA) as appropriate. Significant differences of means are indicated as *p <
0.05, **p < 0.01, and ***p < 0.005.
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CHAPTER 3
HOMOCYSTEINE ACTIVATES mTORC1 SIGNALING THROUGH
INTERACTION WITH LeuRS-Flcn COMPLEX

Amino acid sensitivity of mTORC1 is very well accepted in the field in that
availability of amino acids activates mTORC1, provides its localization on the
lysosomal membrane, and further increases protein synthesis (Hara et al. 1998);
although how amino acid metabolite as modified forms of amino acids affect
mTORC1 activity is yet to be assessed. Homocysteine (de-methylated form of
methionine) is known as a risk factor for AD (Zhuo et al. 2011; Kamat et al.
2015). Mutations in MTHFR, methionine synthase (MS) and CBS are known
factors for AD pathogenesis (Garcia and Zanibbi 2004; Beyer et al. 2003; Zhuo et
al. 2011). All three enzymes mentioned above are functional to remove excess
Hcy from the body; MTHFR provides carbon group to folate which later donates it
to Hcy and facilitates remethylation of Hcy to Met. MS is the main enzyme acting
on Hcy methylation and Met production; whereas CBS is the enzyme that
converts Hcy to cysteine in a two-step transsulfuration pathway. While MS needs
vitamins B12 and B9, CBS needs vitamin B6 to function properly (Jakubowski
2012). Here we elucidate the impact Hcy might have on mTORC1 activity by
assessing the phosphorylation level of mTORC1 substrates and localization of
mTORC1 in the cell.
The amino acid sensitivity of mTORC1 is known to be fulfilled by multiple
amino acid sensors in the cell. While v-ATPase detects the luminal content of
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lysosomal amino acids (Zoncu et al. 2011), LeuRs (Han et al. 2012) and Sestrin2
(Wolfson et al. 2016) are potent Leu sensors in the cytoplasm. In this chapter, we
show a new mechanism for Hcy to be sensed and further regulate mTORC1
activity. We show that Flcn which is known as a GAP for RagC/D (Tsun et al.
2013), interacts with LeuRS and its activity is dependent on amino acid (including
Hcy) availability.

3.1 Results
3.1.1 Homocysteine Treatment Increases Phosphorylation Level of
mTORC1 Substrates
It is well known that Leu is a strong mTORC1 activator which translocates
mTORC1 on the lysosomal membrane where it is in close proximity to Rheb, its
activator (Bar-Peled and Sabatini 2014). Given that mTOR is a kinase, its
activation corresponds to increase in phosphorylation levels of its related
substrates. Thus, to assess mTORC1 activity, the phosphorylation level of
P70/S6K, 4EBP-1, and TFEB were analyzed in western blot analyses of cells
treated with Hcy for three hours. HEK293T cells and iPSC-derived human
neurons were main cell lines utilized for completion of this research project. Cells
were cultured in RPMI media supplemented with Leu, Glu and 10% dialyzed FBS
in which mTORC1 is fully active. Leucine withdrawal from the above media
renders mTORC1 inactive and diffused in the cytoplasm; thus, we used it as
starvation media for our experiments. In Hcy-treated conditions, Leu was
substituted by Hcy; in this manner, we were able to evaluate and compare
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mTORC1 activity in presence of Leu or Hcy. Homocysteine-treated cells showed
increased mTORC1 activity compared to starved cells as was detectable by
measuring the phosphorylation levels of P70/S6K, 4EBP-1, and TFEB (Figure
3.2 A, B, and C). The activity of mTORC1 was up-regulated in presence of Leu
and Hcy as compared to Leu alone (Figure 3.3 A, B, and C). These data showed
Hcy ability to activate mTORC1 in absence or presence of Leu. Of note,
immunoblot analyses of P70/S6K in human brain lysates of AD versus control
patients showed increase of mTORC1 activity in AD patients (Figure 3.1 A),
which were diagnosed with a high level of plasma Hcy (Zhuo et al. 2011; Li, Chu,
and Barrero 2014; Kamat et al. 2015). However, levels of other mTORC1-related
factors such as TSC2 and Rheb which inhibit and activate mTORC1 respectively
did not show a significant difference between control and AD samples (Figure 3.1
B and C).
To elucidate the pathway through which Hcy leads to mTOR activation,
and to rule out the possibility of Akt signaling activation by Hcy, Akt (T308)
phosphorylation level was measured in immunoblot analyses of cells treated with
ascending concentrations of Hcy. Although phospho-p70/S6K levels increased
proportionally to increased concentrations of Hcy, phospho-Akt (T308) did not
change significantly (Figure 3.4). Similarly, phospho-Akt (T308) and (S473) were
probed in Cbs deficient and wild-type mice brain lysates; neither phospho-Akt
(T308) (as a marker for growth factor signaling) nor phospho-Akt (S473) (as a
readout for mTORC2 signaling) changed significantly between mutant and
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normal mice (Figure 3.5 A and B). Interestingly, we did not observe significant
changes of P-AKT (S473) in AD patients, as well (Figure 3.6).

Pp70/actin

A
4

***

3
2
1
0
Cont.

AD

B

C

Figure 3.1 mTORC1 is activated in postmortem brain samples of Alzheimer’s
disease patients. A) The phosphorylation level of P70S6Kinase increased
significantly compared to control patient samples. B and C) TSC2 (mTOR
inhibitor) and Rheb (mTORC1 activator) protein levels did not change
significantly between control and AD patients. Bar graphs represent a
quantitative analysis of protein levels assessed by immunoblot analyses. Data
are means +/- SEM (n = 3 independent experiments). ***P ≤ 0.005.
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Figure 3.2- A, B, C Homocysteine up-regulates mTORC1 activity in absence of
leucine. HEK293T cells were treated with RPMI media supplemented with Glu,
dialyzed FBS and Hcy in absence of Leu (RPMI starvation media). A)
Phosphorylation level of P70/S6kinase increased in Hcy-treated HEK293T cells
which was indicative of mTORC1 hyperactivation (Leu: 3.1 +/- 0.4 -fold; Hcy: 2.7
+/- 0.3-fold; P = 0.004). B) Phospho-4EBP-1 was measured in western blot
analyses as an indicator of mTORC1 activity. Hcy increased P-4EBP-1 level in
HEK293T cells (Leu: 2.4 +/- 0.3-fold; Hcy: 3 +/- 0.4-fold; P < 0.01). C) TFEB
phosphorylation level was assessed to determine mTORC1 activity. PhosphoTFEB appeared upon Hcy treatment while it was not present in starvation media
without Hcy (Leu: 2.1 +/- 0.3-fold; Hcy: 3.2 +/- 0.4-fold; P = 0.014). Bar graphs
represent a quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 6 independent experiments). *P ≤ 0.05,
**P ≤ 0.01, and ***P ≤ 0.005.
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Figure 3.3- A, B and C Homocysteine and leucine collaboratively activate
mTORC1. HEK293T cells were treated with RPMI media supplemented with Leu,
Glu, dialyzed FBS (RPMI complete media) and Hcy. A) Phospho-P70/S6K
increased in media contained both Hcy and Leu. B) Phospho-4EBP1 increased
in presence of Hcy and Leu in the media. C) Homocysteine and Leu together
gave rise to the formation of a more phosphorylated form of TFEB. Bar graphs
represent a quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 6 independent experiments). *P ≤ 0.05.
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Figure 3.4 Homocysteine regulates mTORC1 activity without changing the
phospho-Akt pathway. HEK293T cells were treated with increasing
concentrations of Hcy added to RPMI starvation media. Cell lysates were
subjected to western blot analyses followed by probing with P-AKT (pT308)
antibody. Homocysteine did not change phosphorylation levels of AKT(T308)
while it did change phospho-P70/S6kinase levels, significantly (0.34 mM: 1.5 +/0.2-fold; 4.25 mM: 3.5 +/- 0.4-fold). Bar graphs represent a quantitative analysis
of protein levels assessed by immunoblot analyses. Data are means +/- SEM (n
= 6 independent experiments). **P ≤ 0.01, and ***P ≤ 0.005.
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A

B

Figure 3.5- A and B Homocysteine does not impact phospho-AKT pathway in
𝐶𝑏𝑠−/− mice. A) Relative phospho-Akt protein levels associated with mTORC2
signaling (phospho-Serine 473), as well as B) phospho-Akt indicative of growth
factor receptor signaling (phospho-Threonine 308) did not significantly change in
𝐶𝑏𝑠 −/− mouse brains compared to control littermates. Immunoblots represent
separate runs of protein samples from five control and five knockout brains. Bar
graphs represent quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 3 independent experiments).
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Figure 3.6 Phosphorylated levels of AKT473 do not change in Alzheimer’s
disease patients. Human brain lysates of Alzheimer’s and control patients were
assessed in western blot analyses for determination of P-AKT473 levels. No
significant changes were detected between our experimental groups. Bar graphs
represent a quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 3 independent experiments).

3.1.2 Mechanistic Target of Rapamycin is not Activated by HomocysteineThiolactone
Hcy-thiolactone, a reactive Hcy metabolite, has been detected in patients with
high serum Hcy (HHcy). The reason for Hcy conversion to Hcy-thiolactone arises
from Hcy editing process which happens by AARS through which Hcy takes a
cyclized conformation. Homocysteine-thiolactone (a cyclic thioester) is known as
a reactive component which attacks free amino groups of protein lysine residues
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(Jakubowski 2015). The hyperactivity of Hcy-thiolactone leads to protein damage
and precipitation, hence is proposed to have pathological effects (Jakubowski
1999; Akchiche et al. 2012); however, in our study, we showed that Hcythiolactone did not regulate mTORC1 activity. HEK293T cells were treated with
same concentrations of Hcy-thiolactone as Hcy in media with or without Leu. The
activity of mTORC1 did not change in presence and absence of Hcy-thiolactone
which was assessed by measuring the phosphorylation level of p70/S6K (Figure
3.7).

Figure 3.7 Homocysteine-thiolactone does not affect mTORC1 activity.
HEK293T cells were cultured in RPMI complete and starvation media with or
without Hcy-thiolactone. Phospho-P70/S6kinase was assessed by western blot
analysis. No significant changes were observed in Hcy-thiolactone versus control
treatments. Bar graphs represent a quantitative analysis of protein levels
assessed by immunoblot analyses. Data are means +/- SEM (n = 3 independent
experiments).
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To confirm the data that identified Hcy-thiolactone as not incorporating into
mTORC1 activation, Blmh/Pon1 deficient mice which lack both important
enzymes to hydrolase Hcy-thiolactone were fed with Met, as a Hcy precursor,
and brain lysates were applied to western blot analyses. It has been shown that
these transgenic mice have a high concentration of Hcy-thiolactone in their
plasma (Borowczyk et al. 2012). Normal mice fed with Met were used as a
control that demonstrated higher mTORC1 activity compared to normal mice fed
with water. However, Met-treated mice which were deficient in Blmh/Pon1
enzymes did not show significant changes in mTORC1 activity compared to
normal mice fed with methionine (Figure 3.8).

Figure 3.8 mTORC1 activity is not affected by homocysteine-thiolactone in-vivo.
Brain lysates of normal mice fed with water or methionine and mice deficient in
Bleomycin/Paraoxonase1 which was fed with methionine were subjected to
western blot analyses. No significant changes in P-p70S6kinase activity were
assessed between the normal and deficient mice fed with methionine. Bar graphs
represent a quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 3 independent experiments).
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Since Hcy is converted to the amino acid cysteine upon accumulation in
the cells, the impact cysteine might have on mTORC1 activity was measured to
specify the effect Hcy has on mTORC1, specifically. HEK293T cells were treated
with RPMI complete and starvation media with or without cysteine. Cells were
lysed further and subjected to western blot analysis. Phospho-p70S6kinase level
was assessed and showed no significant impact on mTORC1 activity (Figure
3.9).

Figure 3.9 Cysteine does not affect mTORC1 activity. The effect of cysteine on
mTORC1 activity was assessed in HEK293T cells by treating with cysteine in
complete and starvation media and performing western blot analyses. No
significant changes were observed in mTORC1 activity between our cysteinetreated versus control cells. Bar graphs represent a quantitative analysis of
protein levels assessed by immunoblot analyses.
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3.1.3 Homocysteine Induces mTORC1 Localization on the Lysosomal
Membrane in Absence of Leucine
mTORC1 localization plays an important role in its activation in that the kinase
needs to tether to lysosomal membranes to become activated (Sancak et al.
2010), so localization of mTORC1 was monitored in immunostaining experiments
by applying mTORC1 and lysosome-associated membrane glycoprotein 2
(LAMP2) antibodies to cells treated with Hcy. In RPMI complete media virtually
all of the mTORC1 co-localized with LAMP2; whereas, in RPMI starvation media
which is deprived of Leu, mTORC1 diffused in the cytoplasm. The addition of Hcy
to RPMI starvation media re-tethered mTORC1 back to the lysosomal
membranes; hence indicating that Hcy can be detected by the amino acid
sensing machinery that binds mTORC1 to LAMP2-positive membranes. Data
were representative of two different cell lines; HEK293T cells (Figure 3.10 A) and
mouse embryonic fibroblast (MEFs) (Figure 3.10 B).
To

further

investigate

the

role

of

Hcy

in-vivo

we

performed

immunohistochemistry on Cbs deficient and wild type hippocampal sections. Cbs
deficient mice showed increased co-localization levels of mTORC1 and LAMP2.
Interestingly, overall protein levels of mTORC1 increased in these mice, whereas
the number of their lysosomes decreased significantly compared to control
littermates (Figure 3.11).
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A

Figure 3.10-A Homocysteine drives mTORC1 localization on lysosomal
membrane. HEK293T cells were treated with RPMI complete and starvation
media with or without Hcy. mTORC1 and LAMP2 antibodies were used to probe
mTORC1 and lysosomes, respectively. DAPI stained nucleus. While mTORC1
was diffused in the absence of Leu in starvation media, it localized on the
lysosomal membrane in media which contained Hcy as a substitution for Leu.
The inset shows magnification of selected fields. Scale bars are 10 µm. A bar
graph is representative of mTOR/LAMP2 co-localization divided by the number of
LAMP2 positive puncta. Data are means +/- SEM (n = 6 independent
experiments). ***P ≤ 0.005.
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Mag.

B

Figure 3.10-B Homocysteine drives mTORC1 localization on lysosomal
membrane. MEFs were treated with RPMI complete and starvation media with or
without Hcy. mTORC1 and LAMP2 antibodies were used to probe mTORC1 and
lysosomes, respectively. DAPI stained nucleus. While mTORC1 was diffused in
the absence of Leu in starvation media, it localized on the lysosomal membrane
in media which contained Hcy as a substitution for Leu. The inset shows
magnification of selected fields. Scale bars are 10 µm.
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Figure 3.11 mTORC1 localizes on lysosomal membrane in 𝐶𝑏𝑠 −/− mouse
brains. Control and 𝐶𝑏𝑠 −/− mouse hippocampal dentate gyrus sections were
stained with mTOR and LAMP2 antibodies as markers for mTOR and lysosomes,
respectively. DAPI stained nucleus. 𝐶𝑏𝑠 −/− mice hippocampi showed higher
mTORC1 and LAMP2 co-localization compared to their control littermates (3.7 +/0.5-fold vs. controls; P = 0.045). The bar diagram is representative of the number
of mTOR and LAMP2 in control and knockout mice. The representative plot
profile shows co-localization of mTOR and LAMP2 in 𝐶𝑏𝑠 −/− and control
hippocampi; trendline indicates the average co-localization in the given image.
Data are means +/- SEM (n = 5 mice per group). Scale bars are 20 µm. *P ≤
0.05.
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3.1.4 Leucyl-tRNA Synthetase and Folliculin Interact as a Permanent
Complex
Leucyl-tRNA synthetase is not only known as a facilitator of tRNA-amino acid
binding but also is recognized as a Leu sensor in the cell (Han et al. 2012). The
affinity of Hcy in binding to LeuRS during the editing process of Hcy by LeuRS
(Jakubowski 2012) raised the possibility that Hcy relays the signal to mTORC1
through LeuRS. Although GAP activity of LeuRS toward Rag C was also
proposed by Han et al (Han et al. 2012), the results could not be reproduced by
other research groups in the field. Shortly after, Tsun et al introduced Flcn as a
potent GAP for Rag C and D (Tsun et al. 2013). During this dissertation we
tested the hypothesis that LeuRS and Flcn might interact with each other in an
amino acid-dependent manner. To check this hypothesis we performed coimmunoprecipitation assays testing whether Flcn would bind to LeuRS under
certain metabolic conditions. For this purpose, HEK293T cells were transfected
with Flcn-dTomato construct and treated in RPMI complete and starvation media
with or without Hcy. Following immunoprecipitation, immunoblot analyses were
performed to detect endogenous levels of LeuRS. Notably, we found the
constitutive interaction between LeuRS and Flcn but did not detect a change in
such interaction upon different amino acid treatments or in the starvation media
(Figure 3.12 A).
To confirm our data, reciprocal immunoprecipitation was performed in
which HEK293T cells were transfected with LeuRS-Flag and endogenous Flcn
was probed on western blot analyses. The same constitutive interaction was
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detected between LeuRS and Flcn in all treatments which indicated that Flcn and
LeuRS indeed associate in a complex (Figure 3.12 B).

A

B

Figure 3.12-A and B LeuRS interacts with Flcn to form a complex, permanently.
A) HEK293T cells were transfected with LeuRS-Flag plasmid and treated with
RPMI complete and starvation media with or without Hcy. Cell lysates were
subjected to Immunoprecipitation analyses followed by probing with Flcn
antibody in western blotting. B) Whereas, reverse immunoprecipitation were
applied by over-expression of Flcn-dTomato followed by LeuRS antibody staining
in western blot analyses. Data is indicative of LeuRS and Flcn interaction in
presence and absence of Leu or Hcy, constitutively. IgG pull-down was done as
a control for immunoprecipitation. (n = 5 independent experiments).
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3.1.5 Leucyl-tRNA Synthetase-Folliculin Complex Interacts with Rag C
Conditionally
Folliculin, a tumor suppressor has been implied to have GAP activity toward Rag
C/D; in that Flcn switches GTP-bound form of Rags for GDP and detaches from
the lysosomal membrane as amino acids are replenished in the cytoplasm (Tsun
et al. 2013). Here we provided evidence that Flcn localization is dependent on
Hcy or Leu availability in the cell through two different experimental approaches.
First, we examined the possibility of LeuRS-Flcn complex conditional interaction
with Rag C. We performed immunoprecipitation analyses by transfecting
HEK293T cells with RagC-HA construct and probing western blots with Flcn and
LeuRS antibodies. The potent interaction between the complex and Rag C was
observed only in absence of Leu or Hcy (Figure 3.13 A). Rag C constitutively
active and dominant negative mutants were used as controls for the experiment.
Reciprocal immunoprecipitation assays were conducted by transfecting the cells
with LeuRS-Flag following by evaluation of endogenous Rag C levels in
immunoblot analyses. Intense interaction between LeuRS-Flag and Rag C was
detected in cells treated with starvation media. Whereas, LeuRS-Flag and Rag C
interaction was virtually lost in presence of Leu, Hcy or both (Figure 3.13 B).
In an alternative approach, localization of Flcn was assessed in confocal
immunofluorescence analyses. We used Flcn antibody to check endogenous
levels of Flcn (Figure 3.14 A) or transfected HEK293T cells with Flcn-dTomato
construct to investigate the localization of exogenous overexpressed Flcn (Figure
3.14 B). Cells were treated with RPMI complete and starvation media with or
without Hcy. Folliculin and LAMP2 antibodies were applied to monitor Flcn and
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lysosomes, respectively (Figure 3.14 A). In order to inhibit LeuRS-driven
mTORC1 activity, leucinol, a Leu derivative, was applied which competes with
Leu in binding to LeuRS (Han et al. 2012). Data depicted increased colocalization of Flcn and lysosomes in starvation media and in leucinol treated
cells even in presence of Hcy; while Flcn was diffused in the cytoplasm of cells
treated with Leu or Hcy (Figure 3.14 A). We observed the same pattern of
overexpressed Flcn localization in the cells according to amino acid and Hcy
availability (Figure 3.14 B).
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Figure 3.13-A and B LeuRS-Flcn complex binds to RagC conditionally. A)
HEK293T cells were transfected with RagC-HA plasmid and treated with RPMI
complete and starvation media with or without Hcy. Co-IP samples were probed
for endogenous LeuRS and Flcn in immunoblot analyses. Data indicates that
LeuRS and Flcn interact with RagC in absence of Leu or Hcy (starvation media).
Cells were also transfected with RagC-GTP-bound (dominant negative) and
RagC-GDP-bound (constitutively active) as negative and positive controls,
respectively. IgG pull-down was done as a control for immunoprecipitation. (n = 3
independent experiments). B) HEK293T cells were transfected with LeuRS-Flag
in complete and starvation media with or without Hcy. Further, immunoblots were
probed for endogenous RagC. RagC showed the highest interaction with LeuRS
in absence of both Leu and Hcy.
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Endogenous Flcn staining
A

Figure 3.14-A Folliculin diffuses in the cytoplasm in presence of homocysteine.
HEK293T cells were examined for endogenous Flcn. Cells were cultured in RPMI
complete and starvation media with or without Hcy. Leucinol was used as an
mTORC1 inhibitor in presence of Hcy. Flcn and LAMP2 (as a lysosomal marker)
antibodies were used in immunostaining experiments. DAPI stained nucleus.
Flcn (white arrowheads) resided on lysosomal membrane in absence of Leu or
Hcy, but diffused in the cytoplasm in presence of either of them. Magnifications of
selected areas are shown on the right. Scale bars are 10 µm.
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Exogenous Flcn staining
B
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Figure 3.14-B Folliculin diffuses in the cytoplasm in presence of homocysteine.
HEK293T cells were transfected with Flcn-dTomato. Cells were cultured in RPMI
complete and starvation media with or without Hcy. Leucinol was used as an
mTORC1 inhibitor in presence of Hcy. LAMP2 (as a lysosomal marker)
antibodies were used in immunostaining experiments. DAPI stained nucleus.
Flcn resided on lysosomal membrane in absence of Leu or Hcy, but diffused in
the cytoplasm in presence of either of them (Hcy starvation conditions: 0.7 +/- 0.1
vs. Leu: 0.1 +/- 0.002 and Hcy: 0.2 +/- 0.04; P = 0.01). Bar diagram is
quantitative analyses of Flcn-LAMP2 co-localization divided by the number of
LAMP2-positive puncta. Data are means +/- SEM (n = 6 independent
experiments). Scale bars are 10 µm. **P ≤ 0.01.

3.1.6 Sestrin2 Protein Levels are not Affected by Homocysteine
Sestrin2 has been implicated as a Leu sensor which is capable of binding to Leu
and activating mTORC1 (Wolfson et al. 2016). In general, Sestrin2 is an
interacting partner for GATOR2 (an mTOR activator) and prevents mTORC1
activity by disrupting GATOR2 function (Chantranupong et al. 2014). In presence
of Leu, Sestrin2 loses interaction with GATOR2, renders induction of GATOR2GATOR1 interaction and attenuation of GATOR1-inhibitory effects on mTORC1
which leads to increase in mTORC1 activity; thus the binding ability of Sestrin2 to
Leu is necessary for it to activate mTORC1 (Chantranupong et al. 2014; Wolfson
et al. 2016).
In order to evaluate if the Hcy regulates Sestrin2 expression level in the
cell, the protein levels of Sestrin2 were assessed in HEK293T cells upon
treatment with Hcy. Data showed no significant change in Sestrin2 protein levels
when cells were exposed to Hcy (Figure 3.15 A). Similarly, brain lysates of Cbs
deficient mice did not show alterations in Sestrin2 levels compared to wild-type
mice (Figure 3.15 B).
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Figure 3.15-A Homocysteine does not influence Sestrin2 protein expression
levels. HEK293T cells were treated with different concentrations of Hcy. Sestrin2
protein levels did not change with Hcy treatments. Bar graphs represent a
quantitative analysis of protein levels assessed by immunoblot analyses. Data
are means +/- SEM (n = 3 independent experiments).
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Figure 3.15-B Homocysteine does not influence Sestrin2 protein expression
levels. Cbs knockout brain lysates were assessed for the levels of Sestrin2
protein. Sestrin2 protein levels did not change in hyperhomocysteinemic mice
brain samples. Bar graphs represent a quantitative analysis of protein levels
assessed by immunoblot analyses. Data are means +/- SEM.

3.2 Conclusion
mTORC1 is capable of detecting the availability of amino acids in the cytoplasm
through the complex machinery residing on the lysosomal membrane (Settembre
et al. 2013). In this chapter, it was shown that mTORC1 is capable of sensing
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cellular Hcy. Additionally, we proposed the interaction between LeuRS and Flcn
in a constitutive complex to which Hcy bound and induced cellular translocation
of the complex; LeuRS and Flcn lost binding to RagC when Hcy was present.
This notion lent support to the hypothesis that LeuRS-Flcn complex acts as an
alternative machinery which substitutes mTORC1 on the lysosomal membrane in
starvation conditions. Further, we showed that Hcy-mediated mTORC1 activity
was only specific to Hcy and not to Hcy metabolites in the cell such as Hcythiolactone and cysteine. Finally, the protein levels of Sestrin2, a Leu sensor in
the cytoplasm did not significantly change in response to Hcy. Overall, in this
chapter, we showed that the amino acid metabolite Hcy is a potent inducer of
mTORC1 activity and presented a molecular complex that could sense its
availability.
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CHAPTER 4
ACUTE AND CHRONIC HOMOCYSTEINE TREATMENTS INHIBIT
AUTOPHAGY INDUCTION THROUGH INACTIVATION OF ULK1 AND TFEB

Autophagy is a cellular "self-eating" process that clears cytosolic protein
aggregates and defective organelles and begins by the formation of a double
membranous phagophore. In this process, proteins such as LC3 and P62 play
role in phagophore maturation and autophagosome formation. Further,
autophagosomes fuse with lysosomes to lyse their contents and provide amino
acids and energy available to the cells (Glick, Barth, and Macleod 2010).
Mechanistic target of rapamycin as a master regulator of nutrient signaling
controls autophagy through phosphorylation of TFEB (Settembre et al. 2012;
Martina et al. 2012) and ULK1 (Kim et al. 2011). During starvation conditions,
mTORC1 is inactive and TFEB is no further phosphorylated; during these
conditions, phospho-TFEB moiety is dephosphorylated by calcineurin, a required
step for TFEB translocation into the nucleus. Consequently, active TFEB enters
the nucleus and transcribes genes encoding autophagosome and lysosomal
biogenesis. On the other hand, ULK1 interaction with AMPK is necessary for
autophagy initiation which is impinged by mTORC1-mediated phosphorylation of
ULK1 at Ser 757 (Kim et al. 2011). Since we showed that Hcy regulates
mTORC1 activity, we investigate the consequences of Hcy-mediated mTORC1
activation on the autophagy pathway in acute Hcy-treated or chronic
hyperhomocysteinemic cells and mouse tissue.
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4.1 Results
4.1.1 Acute Homocysteine Treatments Impinge Autophagy Induction
Unc-51 like autophagy activating kinase-1 (ULK1) and TFEB are two known
autophagy regulators and mTORC1 substrates (Kim et al. 2011; Settembre et al.
2012). We assessed the rate of autophagy induction in short term Hcy-treated
cells. Cells co-transfected with LC3-RFP and LAMP1-GFP constructs were
treated with Hcy for three hours and imaged searching for LC3-positive
organelles. Homocysteine-treated cells showed a reduced number of LC3
punctal staining compared to cells treated with control complete media. Torin, a
specific mTOR inhibitor, and potent autophagy inducer, was added to Hcycontaining medium and could reverse the diffused LC3 by increasing the number
of LC3-positive organelles which co-localized with LAMP1 (late endosome and
lysosomal marker) (Figure 4.1).
Since mTORC1 phosphorylates ULK1 relatively quickly, we analyzed
levels of phospho-ULK1 along with a lipidated form of LC3 (LC3II) in western
blots. To decide what time point is the best for short-term Hcy treatments,
HEK293T cells were treated with the same concentration of Hcy over different
periods of time (1h, 2h, 3h, 4h, and 5h). Evaluation of cell lysates on western blot
identified three hours of treatment with Hcy as a time point showing a reliable
increase of mTORC1 activity in-vitro, as was assessed by evaluation of Pp70S6/kinase level relative to protein loading control (Figure 4.2). To assess the
true amount of LC3II formation in the autophagosomes prior to its lysosomal
fusion and degradation, we performed autophagy flux assays. In these assays, a
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Figure 4.1 Acute treatments of homocysteine impinges autophagy induction.
HEK293T cells were co-transfected with LC3-RFP and LAMP1-GFP constructs
and treated with RPMI complete media with or without Hcy. Torin was used as a
specific mTOR inhibitor. Chloroquine was utilized as a positive control for
malfunctioned lysosomes. DAPI stained nucleus. Homocysteine reduced
formation of LC3-positive autophagosomes (white arrowheads), while Torin
rescued this phenotype and increased the formation of LC3 puncta (Leu, control:
5.2 +/- 0.6 and Leu+Hcy: 1.1 +/- 0.1; P = 0.05), and (Torin in Hcy-treated cells:
14.5 +/- 1.6; P = 0.04). Bar diagram represents quantitative analyses of LC3positive organelles per cell (red) and LC3-LAMP1 co-localization divided by the
number of LAMP1-positive puncta (yellow). Data are means +/- SEM (n = 3
independent experiments). Scale bars are 10 µm. *P ≤ 0.05 and **P ≤ 0.01.
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Figure 4.2 Three hours of homocysteine treatment show the strongest impact on
mTORC1 activity. Treatment of HEK293T cells with same concentrations of Hcy
at different time points showed that 3 hours of Hcy-treatments had the highest
impact on mTORC1 activity which was measured by evaluation of relative Pp70S6kinase protein levels. Bar graphs represent a quantitative analysis of
protein levels assessed by immunoblot analyses.

lysosome inhibitor such as Chloroquine was combined with experimental
treatments to let us compare the overall amount of LC3II generated by cells and
becomes degraded in lysosomes (Mizushima, Yoshimori, and Levine 2010).
Interestingly, cells exposed to Hcy for three hours showed considerably
decreased levels of LC3II and relatively increased levels of phosphorylated ULK1
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on Ser 757 (Figure 4.3). The connection between the two comes from the fact
that phosphorylation of ULK1 on Ser 317 & Ser 777 by AMPK is necessary for
induction of autophagy whereas ULK1 phosphorylation on Ser 757 inhibits
autophagy induction, LC3I lipidation, and conversion to LC3II (Kim et al. 2011).

Figure 4.3 Acute homocysteine treatments inhibit autophagy induction by
increasing the level of phospho-ULK1. Human neuroprogenitor cells were treated
with Hcy, Leu (for 3 hours) and Chloroquine (for 1 hour). Homocysteine clearly
reduced the formation of LC3II (0.4 +/- 0.03-fold; P = 0.04) which was in parallel
with an increase in the formation of P-ULK1 (1.5 +/- 0.03-fold; P = 0.05) which
was indicative of less autophagy induction in the cells. Chloroquine treated cells
showed a thicker LC3II band in absence of Hcy compare to its presence. Bar
graphs represent a quantitative analysis of protein levels assessed by
immunoblot analyses. Data are means +/- SEM (n = 3 independent experiments).
*P ≤ 0.05.
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An alternative approach to validate the hypothesis of autophagy inhibition
by Hcy was to employ ptf-LC3 constructs, a tandem-fluorescent LC3 sensor as
established by Kimura et al (Kimura, Noda, and Yoshimori 2007). ptf-LC3 has
been constructed as a fusion protein of LC3, mRFP, and GFP, as such both red
and green fluorescents are monitored in neutral pH environment whereas GFP is
quenched in acidic organelles and only red is visible. Thus, in this experiment red
organelles in merge channel are representative of functional lysosomes. Human
neuroprogenitor cells were transfected with the construct and treated with RPMI
complete and starvation media with or without Hcy and Chloroquine. Media
containing Hcy reduced number of both red and green LC3-positive organelles
which were indicative of a decline in both LC3 lipidation and autophagosomal
maturation. Chloroquine which interferes with lysosomal acidification was used
as a control for this experiment (Figure 4.4).

4.1.2 Chronic Homocysteine Treatments Interfere with Autophagy Induction
through Modulation of TFEB-Regulated Gene Expression
Autophagy is known to be regulated by mTORC1 also through translation
modulation of the TFEB-regulated genes (Martina et al. 2012). We took different
approaches to test if TFEB is affected by the Hcy-driven mTORC1 activity. We
performed autophagy flux assays to monitor LC3I and II protein levels in
prolonged treatments with Hcy (16-24 h). Both LC3I and II significantly
decreased in Hcy-treated cells as compared to cells treated with control media.
The combination of treatments with Chloroquine depicted the reduced formation
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of LC3II compared to Chloroquine treatments alone which were indicative of a
reduction in autophagy induction (Figure 4.5). To analyze further the impact of
long-term Hcy treatment on cells, we tested the protein levels of TFEB-target
genes in wild type and Cbs deficient mouse brain lysates. Analyses showed
reduced protein levels of both LC3I and p62 in mutant versus normal mice
(Figure 4.6). Both of these experiments delineated the Hcy possible impacts on
TFEB activation which are further assessed in this chapter.
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Figure 4.4 Homocysteine interferes with autophagy induction. Human
neuroprogenitor cells were transfected with tandem-fluorescent mRFP-GFP-LC3
constructs and treated with RPMI complete and starvation media with or without
Hcy. DAPI stained nucleus. Red arrowheads showed acidified autophagosomes
while yellow ones were indicative of immature autophagosomes; both red and
yellow puncta were reduced in presence of Hcy in the media which was
indicative of inhibition of autophagy induction and maturation of autophagosomes
(Leu (red): 3.1 +/- 0.3, Leu (green): 1.1 +/- 0.1; Hcy (red): 1.4 +/- 0.1, Hcy
(green): 1.3 6 0.1; P = 0.04). Bar diagram is quantitative analyses of LC3 red and
green signals per cell. Data are means +/- SEM (n = 3 independent
experiments). Scale bars are 10 µm. *P ≤ 0.05.

Figure 4.5 Autophagy is inhibited by homocysteine, chronically. Human
neuroprogenitor cells were treated with Leu, low concentration of Hcy (overnight)
and Chloroquine (for 1 hour). Homocysteine clearly reduced the formation of
LC3I (Leu/Hcy/CQ: 0.46 +/- 0.01-fold vs. Leu/CQ: 1.7 +/- 0.2-fold; P = 0.03) and
LC3II (Leu/Hcy/CQ: 0.9 +/- 0.1-fold vs. Leu/CQ: 2.2 +/- 0.2-fold; P = 0.04) which
were indicative of inhibition in autophagy induction and flux over longer period of
Hcy-treatments. Chloroquine treated cells showed accumulation of LC3II in
absence of Hcy. Bar graphs represent a quantitative analysis of protein levels
assessed by immunoblot analyses. Data are means +/- SEM (n = 3 independent
experiments). *P ≤ 0.05.
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Figure 4.6 TFEB-target gene protein levels decreased in 𝐶𝑏𝑠 −/− mouse
samples. Brain lysates of Cbs deficient and wild type mice were subjected to
western blot analyses. TFEB target genes (P62 and LC3) decreased in 𝐶𝑏𝑠 −/−
mice samples compare to control ones (LC3, 0.5 +/- 0.06, P = 0.01; p62, 0.6 +/0.07 vs. 1.0 +/- 0.01 in controls, P = 0.04). Bar graphs represent quantitative
analysis of protein levels assessed by immunoblot analyses. Data are means +/SEM (n = 4 independent experiments). *P ≤ 0.05 and **P ≤ 0.01.

4.1.3 Transcription Factor EB Activity is Impaired in Homocysteine-Treated
Cells
As a transcription factor, TFEB functions in the nucleus; mTORC1 kinase activity
inhibits TFEB activation by maintaining TFEB in the cytoplasm far from its target
genes (Martina et al. 2012). To assess TFEB activity we used four times CLEAR
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element upstream of the Firefly-luciferase gene to which promoter TFEB bound
and drove transcription of

the CLEAR gene network and luciferase,

concomitantly. Human neuroprogenitor cells were transfected with the 4xCLEAR
luciferase reporter construct and treated with ascending concentrations of Leu or
Hcy overnight, followed by measurement of luciferase activity, representing
CLEAR network activity. Data revealed a reduction in the network activity
coordinated with increased concentrations of Leu and Hcy (Figure 4.7 A).
Leucine showed stronger inhibitory effects on TFEB activity since the activity was
attenuated more potently with Leu compared to same concentrations of Hcy
(Figure 4.7 B). We also tried to remove Leu and Hcy after overnight treatments to
see how fast TFEB activity was rescued. Our data showed that Leu removal
retained TFEB activity faster compared to Hcy (Figure 4.7 C).

4.1.4 Transcription Factor EB Localizes in the Cytoplasm of Cells Treated
with Homocysteine
Given that our data showed a reduction in TFEB activity of cells exposed to Hcy,
we tested the localization of this transcription factor in Hcy-treated cells and
hyperhomocysteinemic

mice

brains.

Mouse

neuroblastoma

cells

stably

expressed TFEB-Flag were treated with Hcy and stained with Flag antibody.
Transcription factor EB is known to shuttle back and forth from cytoplasm to the
nucleus upon presence and absence of amino acids, respectively (Settembre et
al. 2012); we observed a similar TFEB translocation in presence and absence of
Leu. Interestingly, TFEB localized to the cytoplasm of cells starved for Leu but

61

treated with Hcy, while leucinol combination translocated TFEB back to the
nucleus (Figure 4.8).

Figure 4.7- A, B and C CLEAR network activity is attenuated in response to
homocysteine treatments. A) TFEB-driven CLEAR network activity was
measured following transfection of human progenitor neurons with CLEARluciferase construct and treatment with Leu or Hcy overnight. Data revealed a
reduction in the network activity coordinated with increased concentrations of Leu
and Hcy. It also showed that Leu had a stronger effect on inhibition of CLEAR
activity compared to Hcy. B) Equal concentrations of Leu and Hcy were used to
measure their inhibitory effect on CLEAR network activity over time. Data
showed that Leu inhibited the CLEAR network activity faster than Hcy. C) After
feeding the cells with Leu or Hcy overnight, cells were washed off Leu and Hcy
followed by CLEAR activity measurement. Data indicated that Hcy potently
inhibited CLEAR network activity compared to Leu since Leu deprivation showed
a faster increase in the activity of the CLEAR network. Data are means +/- SEM
(n = 4 independent experiments). *P ≤ 0.05 and **P ≤ 0.01.
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Figure 4.8 Homocysteine drives TFEB out of the nucleus in cultured cell. Mouse
neuroblastoma (CAD) cells stably expressed TFEB were treated with RPMI
complete and starvation media with or without Hcy. While in absence of Leu,
TFEB enters the nucleus, Hcy was able to draw TFEB back to the cytoplasm.
Leucinol treatments could rescue the phenotype and translocated TFEB to the
nucleus since leucinol inhibited Hcy effect on mTORC1 activity. Bar diagram
shows the statistical evaluation of nuclear versus cytoplasmic localization of
TFEB in the cells. Scale bars are 20 µm.

Hippocampal sections of 𝐶𝑏𝑠 −/− mice (in particular, dentate gyrus regions)
were stained with TFEB and LAMP2 antibodies and compared with wild type.
Most of the TFEB was observed in the cytoplasm of 𝐶𝑏𝑠 −/− mice which was
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exposed to high Hcy levels in the body whereas in wild type mice TFEB localized
largely in the nucleus (Figure 4.9).

Figure 4.9 Homocysteine inhibits TFEB translocation to the nucleus. 𝐶𝑏𝑠 −/−
versus wild type mice hippocampal neurons were applied to immunofluorescent
staining. TFEB and LAMP2 antibodies were used as TFEB and lysosomal
markers, respectively. TFEB was mostly nuclear in control neurons (72.4 +/- 13
vs. 33 +/- 6% in 𝐶𝑏𝑠 −/−; P < 0.01), while was cytoplasmic in Cbs deficient ones
(67 +/- 10 vs. 28 6 4% in controls; P < 0.01). Bar diagram shows statistical
evaluation of nuclear versus cytosolic localization of TFEB in mouse
hippocampal neurons. Scale bars are 20 µm. Data are means +/- SEM (n = 5
mice per group). **P ≤ 0.01.
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4.1.5 Leucinol Inhibits Homocysteine-Mediated mTORC1 Activity, Driving
Higher Rate of Autophagy Flux
Leucinol is a modified form of Leu with high affinity to bind to LeuRS. It is able to
inhibit Leu binding to LeuRS and therefore inhibit Leu-mediated activation of
mTORC1 (Han et al. 2012). Here, we show that leucinol is a potent inhibitor of
Hcy-mediated effects on amino acid-mTORC1 signaling pathway. Of note,
leucinol relocalized Flcn to the lysosomal membranes (Figure 3.14 A and B) and
translocated TFEB to the nucleus as a possible consequence of mTORC1
inhibition (Figure 4.8). We did further investigation to follow what leucinol
implicated in autophagy pathway. As expected, leucinol inhibited mTORC1
activity in presence of Hcy and induced autophagy which was detectable as a
decrease in LC3I and increase in LC3II formation (Figure 4.10). However, in
order to distinguish if the LC3II increase was due to lysosomal inhibition or high
conversion rate from LC3I to LC3II, we included Chloroquine to inhibit lysosomal
function and assessed the difference in LC3II formation. Data showed that LC3II
accumulation in leucinol treatments combined with Chloroquine was higher
compared to leucinol-treatment alone (Figure 4.11), which implicated that
leucinol did not affect lysosomal function but increased autophagy flux.
Furthermore, we observed a lower rate of proliferation in leucinol-treated
cells compared to cells treated with nutrient-rich media without leucinol (Figure
4.12 A). This effect could be due to inhibition of mTORC1 activity, although it
needs further investigation to assess if leucinol interferes with cell proliferation. In
order to exclude the possibility of mTORC2 inhibition by leucinol, the
phosphorylated levels of AKT (S473) were assessed in cells treated with or
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without leucinol. Data indicated no significant changes in protein levels of P-AKT
(S473) (Figure 4.12 B).

Figure 4.10 Leucinol inhibits homocysteine-driven mTORC1 activity. HEK293T
cells were treated with RPMI complete and starvation media with or without Hcy
and leucinol. Leucinol inhibited mTORC1 activity in presence of Hcy as indicated
by decreased level of phospho-P70/S6Kinase. This leucinol-related mTORC1
inhibition was accompanied by an increase in LC3II protein levels. Bar graphs
represent a quantitative analysis of protein levels assessed by immunoblot
analyses. Data are means +/- SEM (n = 3 independent experiments).
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Figure 4.11 Leucinol increases autophagy flux. HEK293T cells were treated with
RPMI complete and starvation media with or without Hcy/leucinol and
Chloroquine. Chloroquine and leucinol co-treatments increased LC3II formation
compared to leucinol treatment alone which represented leucinol as a component
which increased autophagy induction and flux but had no lysosomal inhibitory
effects. Bar graphs represent a quantitative analysis of protein levels assessed
by immunoblot analyses. Data are means +/- SEM (n = 3 independent
experiments).
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A

B

Figure 4.12- A and B Leucinol reduces cell proliferation without affecting
mTORC2. A) HEK293T cells treated with leucinol showed a reduced rate of cell
proliferation. Bar diagram represents the number of live cells in each treatment.
B) P-AKT473 was assessed to measure mTORC2 activation upon leucinol
treatments. No significant changes were observed between our experimental
groups.
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4.2 Conclusion
Mechanistic target of rapamycin is known to modulate autophagy as autophagy
modulators have been found to be the target of mTORC1 kinase activity (Kim et
al. 2011; Martina et al. 2012). Here we demonstrated that Hcy-positive impact on
mTORC1 activity impinges autophagy through phosphorylation of the two major
autophagy-driving

factors:

ULK1

and

TFEB.

Hyperactive

mTORC1

phosphorylated ULK1 and consequently reduced LC3 lipidation. It also
dampened TFEB-driven transcription of autophagy-related genes. We also
showed leucinol to be a potent inhibitor of the negative Hcy-mediated effects on
autophagy, thereby confirming that Hcy modulates mTORC1-TFEB pathway
through LeuRS.
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CHAPTER 5
HOMOCYSTEINE IS NEUROTOXIC BY PROMOTING FORMATION OF
ABNORMAL PROTEINS

Since high levels of Hcy have been detected in sporadic AD patients (Zhuo,
Wang, and Pratico 2011; Li, Chu, and Barrero 2014; Kamat et al. 2015; Coppedè
2010) a need arose to elucidate the molecular mechanism behind the correlation
between high plasma Hcy concentration and disease progression, which
correlates with aging (Levine et al. 2008; Tucker et al. 2005). Notably, AD
hallmarks including memory loss, the formation of the amyloid deposits, and
phosphorylated tau neurofibrillary tangles, have been correlated with HHcy (Li et
al. 2014), identifying Hcy particularly as a risk factor for AD (Morris 2003;
Pacheco-quinto et al. 2006). The reason for the notion that Hcy is a risk factor for
AD and not the disease marker, arises from the epidemiological studies on AD
patients which demonstrated high concentration levels of Hcy in patients’ plasma
prior to the development of dementia (Seshadri, 2006). Extensive research to
elucidate pathways by which Hcy affects neurons is being carried out; some of
which show that Hcy activates N-methyl-D-aspartate (NMDA) receptors (Lipton et
al. 1997), oxidative stress (Perna, Ingrosso, and Santo 2003) and modification of
DNA methylation (Fuso et al. 2005), all of which being detrimental contributions
of Hcy to the brain. Additionally, Li et al. have proposed two independent
pathways through which Hcy contributes to exacerbation of AD phenotype:
activation of γ-secretase and CDK5 pathways which lead to the formation of βamyloid deposition and accumulation of tau insoluble form, respectively (Li et al.
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2014). Yet, there is no evidence to show whether Hcy-mediated mTORC1
activation and associated inhibition of autophagy lead to the formation of these
specific protein deposits.

5.1 Results
5.1.1 Homocysteine Induces the Formation of Abnormal Proteins
Associated with Alzheimer’s Disease
To identify future drug targets, it is crucial to elucidate the mechanism of Hcy
action in AD pathophysiology, including the formation of β-amyloid and
hyperphosphorylated Tau (Li et al. 2014). Hippocampal sections of 𝐶𝑏𝑠 −/− mice
were assessed for paired helical filaments (PHF) of phospho-Tau which showed
a significant increase compared to wild type littermates (Figure 5.1 A, B and C).
Increase in phospho-Tau was associated with aggregated microtubuleassociated protein 2 (MAP2) in 𝐶𝑏𝑠 −/− mice (Figure 5.1 A). Interestingly,
phospho-Tau tangles partially co-localized with P62-positive autophagosomes
indicating that the recognition of PHF phospho-Tau took place in 𝐶𝑏𝑠 −/− brains
(Figure 5.1 B). Next interesting feature observed for phospho-Tau, was the
morphology as lined up along blood vessels in normal mice, while phospho-Tau
spread out in Cbs deficient mice brain sections, which might be another
implication for abnormal clearance in 𝐶𝑏𝑠 −/− mice (Figure 5.1 C). Similarly,
overall amount of intracellular β-amyloid increased by ≈2.24 fold in knockout mice
as compared to wild type (Figure 5.1 C).
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Figure 5.1- A, B and C Cbs knockout mouse brains show accumulation of
abnormal proteins. A) Paired helical filament phospho-Tau levels increased in
hippocampal areas of 𝐶𝑏𝑠 −/− mice. Microtubule-associated protein 2 (MAP2)
looked punctated and indicated with fewer number of neurons in 𝐶𝑏𝑠 −/− samples
(pTau: 2.8 +/- 0.2-fold, P < 0.005; degen. MAP2: 2.6 +/- 0.2-fold; P < 0.01). B)
pTau and P62 (autophagosomal marker) co-localized in Cbs mutated samples
while overall pTau protein level increased in 𝐶𝑏𝑠 −/− compare to control sections
(p62/pTau colocalization: 0.88 +/- 0.2 in 𝐶𝑏𝑠 −/− vs. 0.22 +/- 0.1 in controls; P =
0.001). C) Cbs knockout hippocampi showed increased levels of β-amyloid as
compared to littermate controls (2.24 +/- 0.15-fold; P < 0.01). Bar diagrams show
statistical evaluation of immunostained sections. Data are means +/- SEM (n = 5
mice per group). **P ≤ 0.01, and ***P ≤ 0.005.

5.1.2 The Homocysteine-Driven Increase in the Level of β-Amyloid is
Reversible by Inhibition of mTORC1 Activity or Induction of Autophagy
Ho et al. previously showed that Hcy exacerbates β-amyloid neurotoxicity in
neurodegenerative diseases such as AD by increasing β-amyloid-mediated
calcium levels in the cytoplasm and induction of apoptosis (Ho et al. 2001). Later,
a link between Hcy and β-amyloid production was made through modification of
γ-secretase activity, one of the enzymes responsible for cleavage of amyloid
precursor protein in process of β-amyloid production (Li et al. 2014). Further
studies revealed that AD phenotypes are reversible by inhibition of mTORC1 with
Rapamycin in mouse models of AD (Spilman et al. 2010). Here, we show that
Hcy enhances β-amyloid protein level through induction of mTORC1 activity and
inhibition of autophagy. The role of autophagy in the prevention of
neurodegeneration has been demonstrated before, as autophagy-deficient mice
showed behavioral abnormality due to loss of neurons in their cerebral and
cerebellar cortices (Komatsu et al. 2006). Employing ELISA assays to detect βamyloid 42 versus 40 levels in cultured human neurons which were treated with
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ascending concentrations of Hcy, we detected an increase in β-amyloid 42/40
levels proportional to Hcy concentrations (Figure 5.2 A). Homocysteine-treated
human neurons were exposed to the mTORC1 inhibitor Rapamycin (Sabers et
al. 1995) or the autophagy-inducing peptide TAT-Beclin1 (Shoji-Kawata et al.
2013) to assess the role of mTORC1 activity and autophagy in amyloid formation
and survival, respectively. Our data indicated a prominent role of mTORC1 and
autophagy in the regulation of β-amyloid levels; as mTORC1 inhibition or
autophagy induction, both reduced the levels of β-amyloid42/40 in our
quantitative analyses (Figure 5.2 B).

5.1.3 Homocysteine is Detrimental to Human Neurons
Autophagy has been identified to be necessary for the maintenance of neuronal
homeostasis, as inhibition of autophagy led to neurodegeneration in Atg7
deficient mice (Komatsu et al. 2006). Given that activation of mTORC1
attenuates autophagy induction, we investigated the role of Hcy-mediated
mTORC1 activity on the viability of human neurons. The viability of the cells was
measured by employing viability assays detecting levels of cellular ATP. The
viability of cultured human neurons exposed to Hcy dramatically decreased
during the fourth days of treatment (Figure 5.3 A), while Rapamycin and TATBeclin1 rescued the neurons (Figure 5.3 B).
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B

Figure 5.2- A and B Homocysteine increases levels of intracellular amyloid in
human neurons. A) Human neuroprogenitor cells were treated with increasing
Hcy concentrations and subjected to ELISA assays. Cellular β-amyloid 42/40
ratio increased proportionally to increasing levels of Hcy concentration (0.05 mM:
1.9 +/- 0.2; 0.5 mM: 2.8 +/- 0.2). B) Rapamycin (mTORC1 inhibitor) and TATBeclin1 (autophagy inducer peptide) decreased the ratio of β-amyloid 42/40 in
HHcy conditions. Data are means +/- SEM (n = 5 independent experiments). *P ≤
0.05 and **P ≤ 0.01.
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B

Figure 5.3- A and B Homocysteine proceeds degeneration of human neurons.
Human neuroprogenitor cells were treated with Hcy for different periods of time
and followed by luciferase-based viability assay measuring the levels of ATP.
Hcy degenerated neurons drastically after four days (A), the phenotype which
was rescued in Rapamycin and TAT-Beclin1 treatments (B). Data are means +/SEM (n = 5 independent experiments). **P ≤ 0.01.
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5.1.4 Unfolded Protein Response is Upregulated in Cbs Deficient Mice
Unfolded protein response (UPR) senses the accumulation of abnormal proteins
and triggers, among other factors, phosphorylation of protein kinase RNA-like
endoplasmic reticulum kinase (PERK) which was proposed to become activated
through the Hcy-mediated pathway (Zhang et al. 2001). Upon PERK activation,
eIF2α

is

phosphorylated

and

induces

the

production

of

ATF4

and

CCAAT/enhancer-binding protein homologous protein (CHOP), a pro-apoptotic
transcription factor (Babcock et al. 2013). Thereby we decided to assess the
amount of CHOP protein level in our Cbs KO mouse brain sections. Mouse
hippocampal sections showed increased formation of CHOP which was
correlated with increased astroglial activation as detected by GFAP staining
(Figure 5.4).

5.2 Conclusion
Formation of β-amyloid and phospho-Tau are considered as hallmarks of AD (Li
et al. 2014). To evaluate neurotoxicity of Hcy, it was crucial to assess its
contribution to the formation of the abnormal proteins. Here we demonstrated
that Hcy indeed led to the formation of β-amyloid and phospho-Tau in
hyperhomocysteinemic mouse brains. These mice had phospho-Tau tangles
spread throughout the cells, while wild-type mice showed decreased levels of
phospho-Tau along blood vessels in the brain. Accumulation of AD-specific
protein deposits in HHcy mouse brains and decreased viability of human neurons
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exposed to Hcy supports the notion that Hcy is likely a driver of AD
pathophysiology. Additionally, we could rescue the phenotype by inhibition of
mTORC1 or activation of autophagy. Our data underlined the importance of
autophagy in neuronal homeostasis. However, future studies need to be
conducted to shed light on the cell death mechanism driven by Hcy.

Figure 5.4 Cbs knockout mice have higher CHOP levels and correlate with
increase in activated astrocytes. CHOP staining increased in hippocampal
sections of Cbs knockout mice which was in parallel with increase in GFAP
staining. Scale bars are 20 um, n=2.
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CHAPTER 6
DISCUSSION AND FUTURE DIRECTIONS

It is noteworthy to elucidate how Hcy as a common disease risk factor
contributes to disease pathogenesis. Homocysteine has been correlated with
cardiovascular disease (Clarke et al. 1991) and neurodegeneration by induction
of apoptosis in neurovascular cells (Kamat et al. 2015; Agnati et al. 2005). The
pathway by which Hcy affects apoptosis is not fully understood. In this
dissertation, we could shed light on one of the possible pathways through which
Hcy is sensed in the cells and leads to the phenotype observed in
neurodegenerative diseases. HEK293T cells and reprogrammed human neurons
were utilized in the presented in-vitro studies while Cbs deficient mice
represented the genetic model with high plasma Hcy concentration levels
(≈300uM) (Choumenkovitch et al. 2002) to perform in-vivo studies.

6.1 Homocysteine Increases mTORC1 Activity and Localization on
Lysosomal Membrane
The relevance of high mTORC1 activity in neurodegenerative diseases has been
proposed in some studies (Rubinsztein 2006; Laplante and Sabatini 2012).
Having that in mind we evaluated the mTORC1 activity of brain lysates obtained
from AD and control patients. Our data revealed hyperactivation of mTORC1 in
disease cases while the protein levels of mTORC1 activator (Rheb) and inhibitor
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(TSC2) remained equal between the experimental groups (Figure 3.1 A, B, and
C). Activation of mTORC1 has been related to various upstream signaling
pathways among which growth factor and amino acid signaling represented the
most crucial ones (Laplante and Sabatini 2012; Khayati et al. 2015). Growth
factors are necessary to inhibit TSC2 deterrent activity toward Rheb (Tee et al.
2003) & (Bar-Peled et al. 2013); whereas amino acids are main players of
placing mTORC1 on lysosomal membrane where Rheb resides to activate
mTORC1 (Reddy et al. 2016; Inoki et al. 2003; Zoncu 2011). Among amino
acids, Leu has the strongest impact on mTORC1 activity, yet is insufficient to
activate mTORC1 by its own (Bar-peled and Sabatini 2014). However, the
influence of amino acid metabolites on mTORC1 activation have not been
addressed yet. Here, we proposed that mTORC1 is capable of sensing Hcy to
up-regulate its activity. Homocysteine-treated cells elevated mTORC1 activity in
presence and absence of Leu (Figure 3.2 and 3.3 A, B and C). Likewise, we
showed that Hcy is capable of inducing mTORC1 recruitment on the lysosomal
membrane (Figures 3.10 A and B). Interestingly, our in-vivo studies in Cbs
deficient mice resembled the phenotype seen in-vitro, in Hcy-treated cells.
Microscopic evaluation in hippocampal regions of Cbs knockout and wild-type
mice revealed an increase in overall levels of mTORC1 in Cbs deficient mice
which co-localized at the lysosomal membrane. Interestingly, the number of
LAMP2 positive organelles decreased which could be a likely consequence of
mTORC1-mediated inhibition of TFEB and associated lysosomal biogenesis.
(Figure 3.11).
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6.2 Homocysteine-Driven mTORC1 Activity is Specific to Homocysteine
Homocysteine-driven mTORC1 activity was assumed to be independent of AKT
signaling pathways, as phosphorylation levels of AKT T308 and S473 did not
change in Hcy-treated cells and Cbs deficient mouse brain lysates (Figure 3.4
and 3.5 A and B). As such, AKT S473 phosphorylation levels were found to be
the same in the analyzed post-mortem brain samples from AD and control
patients (Figure 3.6). These data indicated that the growth factor signaling
pathway and mTORC2 activity were not involved in Hcy-driven regulation of
mTORC1 activity. Given that Hcy is unstable in cells and converts to Hcythiolactone (Jakubowski 1999; Jakubowski 2015; Akchiche et al. 2016), we
designed experiments to assess whether mTORC1 activity can be driven by Hcythiolactone. We detected no significant changes in mTORC1 activity upon
treatment of the cells with Hcy-thiolactone (Figure 3.7). In parallel, mTORC1
activity was measured in mouse brain lysates deficient for Bleomycin and
Paraoxonase1 enzyme activities. These mice had a high level of Hcy-thiolactone
(Borowczyk et al. 2012) but showed no increased mTORC1 activity compared to
control mice fed with Met (Figure 3.8). As Hcy-thiolactone is harshly reactive and
able to bind to lysine residues of proteins, it is known to be detrimental to cells
(Jakubowski 1999; Akchiche et al. 2016). However, our data eliminated the role
of Hcy-thiolactone in activation of mTORC1.
Moreover, we excluded the possibility of mTORC1 hyperactivation due to
the accumulation of amino acids in the cytoplasm, which was the result of
preclusion in protein synthesis, implicated by Hcy similar to cycloheximide. To
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this end, we evaluated the impact of other amino acids such as cysteine on
mTORC1 activity. Cysteine was the final product in process of Hcy conversion by
CBS enzyme but did not exhibit a significant effect on mTORC1 activation
implicating Hcy-driven mTORC1 activity being specific to Hcy (Figure 3.9).

6.3 Homocysteine Induces mTORC1 Activity through Interaction with
LeuRS-Folliculin Complex
Molecular mechanisms through which Hcy affects mTORC1 activity were
investigated in this dissertation. In addition to the regular role of LeuRS in
process of protein translation (Park, Ewalt, and Kim 2005), its ability in binding to
Hcy, although with lower affinity, in process of amino acid editing (Jakubowski
2012), led us to assess the possible way through which LeuRS relays the signal
to mTORC1 upon binding to Hcy. Since Flcn’s GAP activity on Rag C/D was
investigated by Tsun et al. (Tsun et al. 2013), we assessed the possibility of
LeuRS interaction with Flcn. To this end, immunoprecipitation analyses were
performed and could prove the existence of such interaction between the two
proteins; although LeuRs binding to Flcn turned out not to be dependent on the
presence of amino acids in the culture media (Figure 3.12 A and B). Given that
Flcn localization differed upon Leu availability (Petit et al. 2013; Tsun et al. 2013),
Hcy impact on the localization of LeuRS-Flcn complex was assessed in this
research project. Interestingly, our data showed that Hcy was able to diffuse Flcn
in the cytoplasm while was resided on the lysosomal membrane in contact with
Rags in absence of Leu or Hcy (Figure 3.13, 3.14 A and B). Of note, Hcy impact
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on Flcn localization was hampered by employing leucinol, a Leu derivative that
inhibited LeuRS activity (Han et al. 2012), suggesting a mediating role for LeuRS
to activate Flcn in presence of Hcy. Further analysis needs to be conducted to
investigate the mechanism through which LeuRS relays the signal to Flcn.
Another possible factor which could be functional in sensing Leu is
Sestrin2. Sestrin2 was proposed to preclude GATOR2-GATOR1 interaction in
absence of amino acids, releasing GATOR1 to act as a GAP, therefore an
inhibitor for Rag A/B; whereas, Leu binding to Sestrin2 perturbed its interaction
with GATOR2 and rendered Rag A/B active (Wolfson et al. 2016). Sestrin2
contribution to Hcy-mediated mTORC1 activation was assessed by evaluating
Sestrin2

protein

levels

in

Hcy-treated

cells.

There

existed

evidence

demonstrating that prolonged amino acid deprivation promoted Sestrin2
transcription in an ATF4-dependent manner (Ye et al. 2015). Our data suggested
that Sestrin2 protein levels did not change in presence of Hcy, (Figure 3.15 A
and B) indicating first, Hcy was potent in precluding the starvation phenotyperelated upregulation of Sestrin2, and second, there was no plausible induction of
Sestrin2 production caused by Hcy.

6.4 Homocysteine Inhibits Autophagy Induction
through Dampening TFEB Activity
Impairment of autophagy in AD patients has been considered with the
observation

of

enlarged

double

membranous

organelles,

resembling

autophagosomes (Levine et al. 2008; Nixon and Yang 2011). This phenotype is
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correlated with the notion that proteinopathies arise from the accumulation of
protein aggregates in the cytoplasm of neurons observed in most of the human
neuronal pathologies such as AD, Parkinson’s and Huntington’s diseases
(Williams et al. 2006). Given that autophagy can be under the control of
mTORC1 activity through ULK1 (Kim et al. 2011) and TFEB phosphorylation
(Martina et al. 2012; Roczniak-Ferguson et al. 2012), we investigated the impact
of Hcy on autophagy. Our data obtained from autophagy flux assays revealed a
role for Hcy in an increase of phospho-ULK1 which impacted LC3 lipidation
(Figure 4.3). Taking these data into consideration, we concluded that Hcy
inhibited autophagy induction that correlated with decreased formation of LC3positive autophagosomes (Figure 4.1). Given that Torin reversed Hcy-mediated
phenotype by increasing the number of LC3 punctual staining, we proved that
Hcy effect on autophagy was mediated through the activation of mTORC1
(Figure 4.1).
Tandem fluorescent-tagged LC3 (ptf-LC3), a conjugated form of LC3 with
GFP and mRFP fluorescent proteins, was utilized as a marker to distinguish
autophagosomes before and after fusion with lysosomes, the final destination of
autophagic organelles (Kimura, Noda, and Yoshimori 2007). Using this construct,
we could confirm that Hcy inhibited LC3 lipidation and autophagosomal
maturation, as indicated respectively by a reduction in the number of both green
and red organelles (Figure 4.4).
The data we obtained in autophagy assays were based on short Hcytreatments of the cells. However, since HHcy has been correlated with AD
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(Coppedè 2010), it is important to assess effects of chronic exposure to high Hcy
levels. Thus, we examined the rate of autophagy induction in cells exposed to
Hcy, overnight. Interestingly, LC3I & II decreased in the long-term exposure of
cells to Hcy (Figure 4.5), thus led us to look at the activity of the upstream
effector of autophagy induction, TFEB. It is important to note that LC3I levels
were indirect reporters of TFEB-mediated transcriptional activity (Karim,
Kawanago, and Kadowaki 2014). Similarly, reduction in protein levels of LC3 and
p62, also a TFEB-target gene (Sahani, Itakura, and Mizushima 2014), were
observed in hyperhomocysteinemic mice brain samples (Figure 4.6). The data
were corroborated by measuring the activity of TFEB, employing a 4xCLEARluciferase construct, an established reporter for TFEB activity (Sardiello et al.
2009). Cells treated with Hcy or Leu overnight showed a reduction in TFEB
activity (Figure 4.7 A). These data were also confirmed by conducting
experiments that showed cytoplasmic localization of TFEB in Hcy-treated cells or
hyperhomocysteinemic mouse brain samples (Figures 4.8 & 4.9) where we
expect to find TFEB while mTORC1 is active (Martina et al. 2012).

6.5 Elevation in Levels of Abnormal Proteins Correlates
with Cellular Homocysteine Levels
The relevance of high levels of Hcy in plasma and the brain (HHcy) in the
progression of AD has been discussed in the field. First, from the possibility of
Hcy conversion to Hcy-thiolactone, it has been correlated with the pathology of
the disease and production of β-amyloid (Borowczyk et al. 2012). Additionally,
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Borowczyk et al. and Suszynska et al. have proposed Hcy-thiolactone as a
neurotoxic agent whose phenotype was ameliorated by Bleomycin hydrolase
(Borowczyk et al. 2012; Suszynska et al. 2010). Second, Hcy was able to
damage vascular integrity, a phenotype which altered angiogenesis and
increased membrane permeability; both of which have been observed in AD
pathogenesis (Kamat et al. 2015). Li et al. also lent further support to the
hypothesis that Hcy exacerbates AD phenotype; the authors introduced
mechanisms by which Hcy led to the formation of β-amyloid and phospho-Tau by
induction of γ-secretase and CDK5 activities, respectively (Li et al. 2014). An
alternative pathway through which Hcy metabolism leads to formation of βamyloid was discussed by Fuso et al. They showed that reduction of Sadenosine methionine (SAM) in cells deficient from enzymes converting Hcy to
Met (methionine synthase), led to hypomethylation and upregulation of BACE
and PS1 genes; the result is production of more β-amyloid (Fuso et al. 2005).
Interestingly, what we proposed here was unique since was attributed to Hcy
influence on the production of AD-related phenotype through modulation of
mTORC1 activity. The increase in β-amyloid 42, the aggregation-prone form of βamyloid, due to Hcy-treatments were reversed to a normal level by applying
Rapamycin and TAT-Beclin1 (Figure 5.2 A and B); both of which modulated the
mTORC1-autophagy pathway. Of note, our data supported Fuso et al.
hypothesis regarding upregulation of genes related to production of β-amyloid,
since mTOR is the master regulator of protein synthesis. We could also detect an
increase of both β-amyloid and phospho-Tau in Cbs knockout mice (Figure 5.1 A,

87

B and C). Interestingly, the same phenotype was observed in TFEB-deficient
mice (Reddy et al. 2016), unraveled the role of TFEB in the pathway.
Thus, Hcy not only inhibits clearance of protein aggregates through
modulation of TFEB activity, but also increases the production of aggregationprone β-amyloid.

6.6 Homocysteine Contributions to Cell Death
Homocysteine contributions to the cell death in AD has been related to induction
of

cerebral

microangiopathy,

endothelial

dysfunction,

oxidative

stress,

neurotoxicity and apoptosis (Kamat et al. 2015), while neuroinflammation has
been observed prior to neuronal loss. (Walker and Sills 2012). Homocysteine
oxidation due to its sulfur group has been shown in the cytoplasm and culture
media. Oxidation of Hcy led to the formation of reactive oxygen species (ROS)
causing neuroinflammation, apoptosis (Yan et al. 2006) and cerebrovascular
dysfunction (Ataie, Sabetkasaei, and Haghparast 2010; Kamat et al. 2015).
Alternatively, Hcy contribution in disruption of blood-brain barrier has been
correlated with an increase of matrix metalloproteinase enzyme activity and
expression observed concomitantly in Cbs deficient mice (Tyagi et al. 2012). Our
viability assays revealed a role for the mTORC1-autophagy pathway in Hcydriven cell death; since mTORC1 inhibition and autophagy induction could
prevent neuronal death caused by prolonged exposure to Hcy (Figure 5.3 A and
B).
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Given that neurodegeneration was triggered by Hcy, further research
needs to be implicated to decipher the mechanism of Hcy-triggered cell death. A
few possibilities have been proposed earlier; such as induction of oxidative stress
(Yan et al. 2006), deterioration of mitochondrial function by Hcy which led to
apoptosis (Kronenberg et al. 2009), and activation of matrix metalloproteinase
enzymes that perturbed extracellular matrix leading to blood-brain barrier
malfunction (Rhodehouse et al. 2013). Similarly, the role of β-amyloid peptide
aggregation in neuroinflammation, DNA damage, and neuronal cell death has
been evaluated (Kamat et al. 2015; Kruman et al. 2002). Yet, there is no
evidence showing the relevance of Hcy-mediated mTORC1-autophagy pathway
in the procedure of cell death induction.
Given the results presented in this dissertation project, it is noteworthy to
consider the contribution of mTORC1 hyperactivity to cell death. An accumulating
body of evidence supported the notion that mTORC1 inhibition favors longer life
span (Lushchak et al. 2017). mTORC1 hyperactivity increased the load of mRNA
translation leading to enhanced protein production which could lead to the
formation of toxic aggregations in the cell; thus, down-regulation of ribosomal S6
kinase has been shown to attenuate aging process, effectively (Selman et al.
2009). The notion that proteasomal degradation was also dampened upon
mTORC1 activation by decreasing overall protein ubiquitylation (Zhao et al.
2015) and proteasomal chaperones (Rousseau and Bertolotti 2016), gives
support to the hypothesis that chronic mTORC1 activation is detrimental for cells.
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Moreover, the contribution of mTORC1 activity to cell death could be
mediated by chronic attenuation/insufficiency of autophagic clearance; the
pathway which plays a crucial role in the maintenance of neuronal homeostasis
(Rubinsztein 2006; Yue et al. 2009). Other than being an active process of eating
redundant proteins and old organelles, autophagy interacts with other signal
transduction pathways in the cell. For example, the crosstalk between autophagy
and apoptosis is implemented by Beclin1/Bcl2 interaction. While Beclin1 is
essential for initiation and elongation of autophagosomes (Glick et al. 2010;
Liang et al. 2006), Bcl2 inhibits such function. The interaction between Beclin1
and Bcl-2 depends upon multiple factors in the cell such as their expression
level, phosphorylation level and localization where they interact (Marquez and Xu
2012). The alternative interplay of autophagy and apoptosis is given by the proapoptotic function of cleaved Beclin1. Following cleavage, a C-terminal fragment
of Beclin1 enters mitochondria to release pro-apoptotic factors in nutrient-poor
conditions (Wirawan et al. 2010).
Our data indicate that Hcy-mediated cell death requires 4 days (Figure 5.3
A). However, activation of NMDA receptors occurs quickly (Lipton et al. 1997),
whereas Hcy-mediated mTORC1 activation followed by inhibition of autophagy
requires more time to disturb neuronal homeostasis leading to cell death. Similar
observation has been made in Atg7 knockout animals which occurs after 28
weeks of birth (Komatsu et al. 2006), suggesting that not neuronal differentiation
or other developmental processes in the brain are disturbed by autophagy
inhibition but the neuronal homeostasis.
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6.7 Future Directions
Having all these cell death-promoted pathways in mind, there is an alternative
pathway which was also proposed to be triggered in presence of Hcy, the
unfolded protein response (UPR) (Zhang et al. 2001). Our data showed that
CHOP staining is upregulated in Cbs deficient mice which correlates with higher
GFAP staining (Figure 5.4). Future studies need to be done to decipher what cell
types specifically express CHOP. Here we showed that inflammation was
triggered in dentate gyrus of Cbs knockout mice represented by an increase in
activated astrocytes (Figure 5.4). We speculate that loss of MAP2 signaling in
Cbs deficient hippocampi (Figure 5.1 A) is due to induction of inflammatory
response. Our future studies will shed light on the way through which Hcy
initiates inflammation in-vitro and in-vivo. We are planning to do Multiplex assays
in Hcy-treated neurons. Likewise, we will treat methionine-fed mice with Torin to
inhibit mTOR activity and correlate with levels of activated astrocytes (GFAP
staining). We assume that Hcy-mediated mTORC1/autophagy modulation
increases protein accumulation in two ways: by increasing protein synthesis and
decreasing the autophagic clearance of protein aggregates and other cellular
debris which further increases UPR signaling and inflammation.
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6.8 Conclusion
Taken together, data presented in this dissertation show that Hcy upregulates
mTORC1 activity, inhibits autophagic clearance eventually leading to the
formation of pathogenic protein aggregates. The mechanisms delineated in this
work may help developing novel approaches that target components of the
mTORC1 and autophagy pathways to counteract Hcy-induced pathologies.
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